RESOURCE AND PATIENT MANAGEMENT SYSTEM

IHS Clinical Reporting System (BGP)

Selected Measures (Local) Report
Performance Measure List and Definitions

Version 11.0
December 2010

Office of Information Technology (OIT)
Division of Information Resource Management
Albuquerque, New Mexico
## Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Revision</th>
<th>Description</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/9/10</td>
<td>N/A</td>
<td>Distribution to field leads for review.</td>
<td>M. Powers</td>
</tr>
</tbody>
</table>

...
## TABLE OF CONTENTS

Revision History ............................................................................................................ ii

1.0 CRS Selected Measures (Local) Report........................................................................ 1
  1.1 Performance Measures Included in the CRS 2011 National GPRA and PART Report ................................................................. 1
  1.2 CRS Denominator Definitions.................................................................................. 5
    1.2.1 For All Denominators ............................................................................. 5
    1.2.2 Active Clinical Population for National GPRA and PART Reporting ..... 5
    1.2.3 Active Clinical Population for Local Reports .......................................... 6
    1.2.4 User Population for National GPRA and PART Reporting .................... 6
    1.2.5 User Population for Local Reports ......................................................... 6
    1.2.6 Active Clinical CHS Population for National GPRA and PART Reporting (CHS-Only Sites) ....................................................... 7
    1.2.7 Active Clinical CHS Population for Local Reports (CHS-Only Sites) .... 7

2.0 Performance Measure Topics and Definitions ............................................................... 8
  2.1 Diabetes Group ............................................................................................... 8
    2.1.1 Diabetes Prevalence ............................................................................. 8
    2.1.2 Diabetes: Comprehensive Care ............................................................ 9
    2.1.3 Diabetes: Glycemic Control ................................................................. 12
    2.1.4 Diabetes: BP Control ........................................................................... 14
    2.1.5 Diabetes: LDL Assessment ................................................................. 16
    2.1.6 Diabetes: Nephropathy Assessment ................................................... 18
    2.1.7 Diabetic Retinopathy ........................................................................... 20
    2.1.8 Diabetic Access to Dental Services ..................................................... 22
  2.2 Dental Group .................................................................................................... 23
    2.2.1 Access to Dental Services ................................................................... 23
    2.2.2 Dental Sealants ................................................................................... 24
    2.2.3 Topical Fluoride ................................................................................... 25
  2.3 Immunization Group ......................................................................................... 27
    2.3.1 Adult Immunizations: Influenza............................................................ 27
    2.3.2 Adult Immunizations: Pneumovax ....................................................... 28
    2.3.3 H1N1 Immunization Status .................................................................. 30
    2.3.4 Childhood Immunizations .................................................................... 30
    2.3.5 Adolescent immunizations ................................................................... 40
  2.4 Childhood Diseases Group ................................................................................ 47
    2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection . 47
    2.4.2 Appropriate Testing for Children with Pharyngitis .............................. 48
  2.5 Cancer Screen Group ....................................................................................... 50
    2.5.1 Cancer Screening: Pap Smear Rates .................................................... 50
    2.5.2 Cancer Screening: Mammogram Rates .............................................. 52
    2.5.3 Colorectal Cancer Screening ............................................................... 53
2.9.11 Medications Education ................................................................. 155
2.9.12 Public Health Nursing ............................................................... 156
2.9.13 Breastfeeding Rates ................................................................. 158
2.9.14 Use of High Risk Medications in the Elderly ......................... 159
2.9.15 Functional Status in Elders ....................................................... 162
2.9.16 Fall Risk Assessment in Elders ................................................... 163
2.9.17 Palliative Care ........................................................................ 164

Contact Information ........................................................................ 165
1.0 CRS Selected Measures (Local) Report

The performance measure topics and their definitions that are included in the Clinical Reporting System (CRS) 2011 version 11.0 Selected Measures (Local) Report are shown in Section 2.0. Performance measures that are also included in the National Government Performance and Results Act of 1993 (GPRA) and Program Assessment Rating Tool (PART) Report are shown in Section 1.1.

Many performance measure topics include both the Active Clinical and User Population denominators. For brevity, the User Population denominator is not listed separately. To see which topics include the User Population denominator, refer to the CRS Clinical Performance Measure Logic Manual for FY 2011 Clinical Measures.

1.1 Performance Measures Included in the CRS 2011 National GPRA and PART Report

The following performance measures will be reported in the CRS 2011 National GPRA and PART Report.

| Key: Bold font indicates official GPRA measures reported in the National GPRA Report submitted to Office of Management and Budget (OMB) and Congress. |
| Italic font indicates changes from CRS version 10.0 Patch 1. |
| A plus sign (+) indicates that this is not an official GPRA measure but is included in the National GPRA Report provided to OMB and Congress to provide context to a GPRA measure(s). |
| One asterisk prior to the topic (*) indicates that this is not an official GPRA measure and is not included in the National GPRA Report provided to OMB and Congress. This measure is included to provide context to a GPRA measure(s). |
| Two asterisks (**) indicate a PART measure included in the GPRA and PART Report submitted to OMB. |

**DIABETES GROUP**

- Diabetes Prevalence
- +Diabetes Diagnosis Ever
- *Diabetes Diagnosis during GPRA Year
**Glycemic Control**
+ Documented Alc

**GPRA: Poor Glycemic Control**
**GPRA: Ideal Glycemic Control**

**Blood Pressure Control**
* BP Assessed

**GPRA: Controlled BP**

**LDL Assessment**

**GPRA: LDL Assessed**
* LDL <= 100

**Nephropathy Assessment**

**GPRA: Estimated GFR & Quantitative Urinary Protein or History of End Stage Renal Disease (ESRD)**

**Retinopathy Assessment**

**GPRA: Retinopathy Evaluation (No Refusals)**

**DENTAL GROUP**

**Access to Dental**

**GPRA: Annual Dental Visit (No Refusals)**

**Dental Sealants**

**GPRA: Dental Sealants (No Refusals; count; not rate)**

**Topical Fluoride**

**GPRA: Topical Fluoride Application (No Refusals; count; not rate)**

**IMMUNIZATIONS**

**Adult Immunizations (65+): Influenza**

**GPRA: Influenza Immunization**

**Adult Immunizations (65+): Pneumovax**

**GPRA: Pneumovax Ever**

**Childhood Immunizations (19–35 months)**

* Active Clinical Pts w/4:3:1:3:3 (No Refusals)
* Active Clinical Pts w/4:3:1:3:3:1 (No Refusals)
* Active IMM Pts w/4:3:1:3:3 (No Refusals)

*Active IMM Pts w/4:3:1:3:3:1 (No Refusals)

**GPRA: Active IMM Pts w/4:3:1:3:3:1:4 (No Refusals)**
*4 DTaP
*3 Polio
*1 MMR
*3 HiB
*3 Hepatitis B
*1 Varicella
*4 Pneumococcal

CANCER SCREENING

Pap Smear Rates

GPRA: Pap Smear (No Refusals)

Mammogram Rates

GPRA: Mammogram (No Refusals)

Colorectal Cancer Screening

GPRA: Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during report period, Flexible Sigmoidoscopy or DCBE in past 5 years, or Colonoscopy in past 10 years (No Refusals)

*FOBT or FIT

Tobacco Use and Exposure Assessment

*Tobacco Assessment

*Smokeless Users

*Exposed to Environmental Tobacco Smoke (ETS)

Tobacco Cessation

GPRA: Tobacco Cessation Counseling or Smoking Cessation Aid (No Refusals)

*Quit Tobacco Use

*Tobacco Cessation Counseling or Refusal, Smoking Cessation Aid, or Quit Tobacco Use

BEHAVIORAL HEALTH

Alcohol Screening (Fetal Alcohol Syndrome [FAS] Prevention)

GPRA: Alcohol Screening (No Refusals)

Intimate Partner Violence/Domestic Violence (IPV/DV) Screening
GPRA: IPV/DV Screening (No Refusals)

Depression Screening

GPRA: Depression Screening or Mood Disorder Diagnosis (No Refusals)
*Depression Screening
*Mood Disorder Diagnosis

CARDIOVASCULAR DISEASE-RELATED

Obesity Assessment
*Obesity Assessment (No Refusals)
*Assessed as Overweight
*Assessed as Obese
*Assessed as Overweight or Obese

Childhood Weight Control (Children 2–5)
*BMI 95% and Up
*BMI 85–94%
*BMI >= 85%

Comprehensive CVD-Related Assessment

GPRA: BP, LDL, and Tobacco Assessed, BMI, and Lifestyle Counseling (No Refusals)
*Depression Screen

STD GROUP

HIV Screening

GPRA: Prenatal HIV Screening (No Refusals)

OTHER CLINICAL

Breastfeeding Rates
Patients 45–394 days of age screened for infant feeding choice (IFC) at least once.
Patients at least 45–89 days of age screened for IFC at the age of two months.
Patients at least 165–209 days of age screened for IFC at the age of six months.
Patients at least 255–299 days of age screened for IFC at the age of nine months.
Patients at least 350–394 days of age screened for IFC at the age of one year.
**PART: 45–394 days of age who were exclusively or mostly breastfed at two months of age
Patients 45–394 days of age who were exclusively or mostly breastfed at six months of age.
Patients 45–394 days of age who were exclusively or mostly breastfed at nine months of age.

Patients 45–394 days of age who were exclusively or mostly breastfed at the age of one year.

**Note:** Definitions for all performance measure topics included in CRS begin on Section 2.0. Definitions for numerators and denominators that are preceded by “GPRA” represent measures that are reported to OMB and Congress. Definitions for numerators and denominators preceded by “PART” are reported for the OMB PART.

### 1.2 CRS Denominator Definitions

#### 1.2.1 For All Denominators

- All patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template *(DPST option located in the PCC Management Reports, Other section) for CRS* will be excluded automatically for all denominators.

- For all measures except as noted, patient age is calculated as of the beginning of the report period.

#### 1.2.2 Active Clinical Population for National GPRA and PART Reporting

- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the *Clinical Reporting System (CRS) for FY2011 Clinical Measures User Manual* for listing of these clinics.

- Must be alive on the last day of the report period.

- Must be American Indian/Alaska Native (AI/AN)—defined as Beneficiary 01.

- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Contract Health Service (CHS) catchment area.
1.2.3 **Active Clinical Population for Local Reports**

- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the *CRS for FY2011 Clinical Measures User* for listing of these clinics.

- Must be alive on the last day of the report period.

- User defines population type: AI/AN patients only, non-AI/AN, or both.

- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.4 **User Population for National GPRA and PART Reporting**

- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

- Must be alive on the last day of the report period.

- Must be AI/AN—defined as Beneficiary 01.

- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined CHS catchment area.

1.2.5 **User Population for Local Reports**

- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

- Must be alive on the last day of the report period.

- User defines population type: AI/AN patients only, non-AI/AN, or both.

- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
1.2.6 **Active Clinical CHS Population for National GPRA and PART Reporting (CHS-Only Sites)**

- Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- Must be AI/AN—defined as Beneficiary 01. This data item is entered and updated during the Patient Registration process.
- Must reside in a community included in the site’s “official” GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

1.2.7 **Active Clinical CHS Population for Local Reports (CHS-Only Sites)**

- Must have two CHS visits in the three years prior to the end of the report period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the report period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
2.0 Performance Measure Topics and Definitions

The following sections define the performance measure topics and their definitions that are included in the CRS 2011 version 11.0 Selected Measures (Local) Report.

| Note: Bold font indicates official GPRA measures reported in the National GPRA Report submitted to OMB and Congress. |
| Bold italic font indicates new or edited definitions. |
| Bold-Italic-Strikethrough indicates deleted material. |

2.1 Diabetes Group

2.1.1 Diabetes Prevalence

No changes from Version 10.0 Patch 1

Owner/Contact
Diabetes Program/Dr. Marie Russell

National Reporting
NATIONAL (included in National GPRA and PART Report; not reported to OMB and Congress)

Denominator
User Population patients

Numerator
1. Anyone diagnosed with diabetes (POV 250.00–250.93) ever.
2. Anyone diagnosed with diabetes during the report period.

Definition

Age
Age is calculated at the beginning of the report period.

Diabetes Diagnosis
Diabetes diagnosis is defined as at least one diagnosis 250.00–250.93 recorded in the V POV file.

Patient List
Diabetic patients with most recent diagnosis.
2.1.2 Diabetes: Comprehensive Care

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Diabetes Program/Dr. Marie Russell

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominator
Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes (Purpose of Visit [POV] 250.00–250.93) prior to the report period, and at least 2 visits in the past year, and 2 DM-related visits ever.

Numerator
1. Patients with hemoglobin A1c documented during the report period, regardless of result.
2. Patients with blood pressure documented during the report period
3. Patients with controlled blood pressure during the report period, defined as < 130/80. This measure is not included in the comprehensive measure (numerator 8 below)
4. Patients with LDL completed during the report period, regardless of result.
5. Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.
6. Patients receiving a qualified retinal evaluation during the report period.
   Note: This numerator does not include refusals.
7. Patients with diabetic foot exam during the report period.
   Note: This numerator does not include refusals.
8. Patients with A1c and Blood Pressure (BP) assessed and LDL and Nephropathy Assessment and Retinal exam and Diabetic Foot Exam.
   Note: This numerator does not include controlled BP, only BP assessment.

Definition

Diabetes
First POV 250.00–250.93 recorded in the V POV file prior to the report period.
A1c

Searches for most recent A1c test with a result during the report period. If none found, CRS searches for the most recent A1c test without a result.

- A1c defined as:
  - CPT 83036, 83037, 3044F-3046F, 3047F (old code)
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT HGB A1C TAX

BP Documented

- Having a minimum of two BPs documented on non-Emergency Room (ER) visits during the report period.

- CRS uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or two) blood pressures and dividing by three (or two).

- If CRS is not able to calculate a mean BP, it will search for Current Procedural Terminology (CPT) 3074F–3080F documented on a non-ER visit during the report period.

Controlled BP

CRS uses a mean, as described above. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

BP Documented and Controlled BP

If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following CPT codes documented on non-ER visits during the report period:

- **Systolic:** 3074F, 3075F, or 3077F with **Diastolic:** 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.

- The following combination represents BP <130/80 and will be included in the Controlled BP numerator: CPT 3074F and 3078F. All other combinations will not be included in the Controlled BP numerator.
LDL
Finds last test done during the report period; defined as one of the following:
- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
- Logical Observations Identifiers, Names, Codes (LOINC) taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

Nephropathy Assessment
Defined as any of the following:
- Estimated GFR with result during the report period, defined as any of the following:
  - Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
  - LOINC taxonomy
- Quantitative Urinary Protein Assessment during the report period, defined as any of the following:
  - CPT 82042, 82043, or 84156
  - LOINC taxonomy
  - Site-populated taxonomy BGP QUANT URINE PROTEIN

Note: Be sure to check with your laboratory supervisor that the names added to your taxonomy reflect quantitative test values.

- End Stage Renal Disease diagnosis/treatment defined as any of the following ever:
  - CPT 36145, 36800, 36810, 36815, 36818, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90918-90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), or S9339
  - POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.*
  - Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*

Qualified Retinal Evaluation
- Diabetic retinal exam or
- Other eye exam

The following methods are qualifying for this measure:
- Dilated retinal evaluation by an optometrist or ophthalmologist.
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist.
– Any photographic method formally validated to seven standard fields (ETDRS).

**Diabetic Retinal Exam**

Any of the following during the report period:

– Exam Code 03 Diabetic Eye Exam (dilated retinal examination or validated photographic equivalent).

– CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging validated to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.

**Other Eye Exam**

- Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or validated tele-ophthalmology retinal evaluation clinics or

- Non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order:
  – Clinic Codes A2, 17, 18, 64
  – Provider Code 24, 79, 08
  – CPT 67028, 67038, 67039, 67040, 92002, 92004, 92012, 92014
  – POV V72.0
  – Procedure 95.02.

**Diabetic Foot Exam**

- Exam Code 28 Diabetic Foot Exam, Complete

- Non-DNKA visit with a podiatrist (Provider Codes 33, 84 or 25)

- Non-DNKA visit to Podiatry Clinic (Clinic Code 65), or

- CPT 2028F

**Patient List**

Diabetic patients with documented tests, if any.

### 2.1.3 Diabetes: Glycemic Control

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Diabetes Program/Dr. Marie Russell
National Reporting

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators

1. All User Population patients diagnosed with diabetes prior to the report period.
2. **GPRA:** Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, *and* at least 2 visits in the past year, *and* 2 DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least 2 DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   - Never have had a creatinine value greater than 5

Numerators

1. Hemoglobin A1c documented during the report period, *regardless of result.*
2. **GPRA:** Poor control: A1c greater than (> 9.5.
3. Very poor control: A1c equals or greater than (=>) 12.
4. Poor control: A1c greater than (> 9.5 and less than (<) 12.
5. Fair control A1c equals or greater than (=>) 8 and less than or equal to (<=) 9.5.
6. Good control: A1c equals or greater than (=>) 7 and less than (<) 8
7. **GPRA:** Ideal control: A1c less than (<) 7.
8. Without result. Patients with A1c documented but no value.

Definition

**Diabetes**

First Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**

- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.
**A1c**

- Searches for most recent A1c test with a result during the report period. If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.
- If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result.
- A1c defined as:
  - CPT 83036, 83037, or 3044F-3046F, 3047F (old code).
  - LOINC taxonomy.
  - Site-populated taxonomy DM AUDIT HGB A1C TAX.
  - Without result is defined as A1c documented but with no value. CPT 3044F represents A1c < 7 and will be included in the Ideal Control numerator.

**GPRA 2011 Description**

**Poor Glycemic Control:** During FY 2011, achieve the tentative target rate of 18.0% for the proportion of patients with diagnosed diabetes who have poor glycemic control (defined as A1c > 9.5).

**Ideal Glycemic Control:** During FY 2011, achieve the tentative target rate of 32.8% for the proportion of patients with diagnosed diabetes who have ideal glycemic control (defined as A1c < 7).

**Patient List**

Diabetic patients with most recent A1c value, if any.

### 2.1.4 Diabetes: BP Control

**Changes from Version 10.0 Patch 1, as noted.**

**Owner/Contact**

Diabetes Program/Dr. Marie Russell

**National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominators**

1. All User Population patients diagnosed with diabetes prior to the report period
2. **GPRA:** Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least 2 visits during the report period, and 2 DM-related visits ever.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
- Who are 19 or older at the beginning of the report period,
- Whose first ever DM diagnosis occurred prior to the report period;
- Who had at least 2 DM related visits ever,
- With at least one encounter with DM POV in a primary clinic with a primary provider during the report period; and
- Never have had a creatinine value greater than 5.

**Numerator**
1. Patients with BP documented during the report period.
2. **GPRA:** Patients with controlled BP, defined as < 130/80, i.e., the mean systolic value is less than 130 and the mean diastolic value is less than 80.
3. Patients with BP that is not controlled.

**Definitions**

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

**BP Documented**
CRS uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) BPs and dividing by three (or two).

**Controlled BP**
CRS uses a mean, as described above where BP is < 130/80. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.
BP Documented and Controlled BP

If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following CPT codes documented on non-ER visits during the report period:

- **Systolic**: 3074F, 3075F, or 3077F WITH **Diastolic**: 3078F, 3079F, or 3080F. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.
- The following combination represents BP <130/80 and will be included in the Controlled BP numerator: CPT 3074F and 3078F. All other combinations will **not** be included in the Controlled BP numerator.

GPRA 2011 Description

During FY 2011, achieve the tentative target rate of **39.0%** for the proportion of patients with diagnosed diabetes who have achieved blood pressure control (defined as <130/80).

Patient List

List of diabetic patients with BP value, if any.

### 2.1.5 Diabetes: LDL Assessment

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Diabetes Program/Dr. Marie Russell

**National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominators**

1. All User Population patients diagnosed with diabetes prior to the report period.
2. **GPRA**: Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least two visits in the past year, and two DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least 2 DM related visits ever
• With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
• Never have had a creatinine value greater than 5

Numerator

1. **GPRA:** Patients with LDL completed during the report period, regardless of result.
2. Patients with LDL results less than (<) 130.
   • Patients with LDL results less than or equal to (<=) 100.
   • Patients with LDL results 101-129.

Definitions

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**
• Site-populated taxonomy DM AUDIT CREATININE TAX, or
• LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

**LDL**
• CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F;
• LOINC taxonomy
• Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX.
• For numerator LDL <130, CPT 3048F and 3049F will count as meeting the measure.
• For numerator LDL =<100, CPT 3048F will count as meeting the measure.
• CRS Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.
• If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.
GPRA 2011 Description

During FY 2011, achieve the tentative target rate of 68.7% for the proportion of patients with diagnosed diabetes who are assessed for dyslipidemia (LDL cholesterol).

Patient List
List of diabetic patients with documented LDL cholesterol test, if any.

2.1.6 Diabetes: Nephropathy Assessment

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Diabetes Program/Dr. Marie Russell

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. All User Population patients diagnosed with diabetes prior to the report period.
2. **GPRA:** Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least 2 visits in the past year, and 2 DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period,
   - Whose first ever DM diagnosis occurred prior to the report period;
   - Who had at least 2 DM related visits ever,
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period; and
   - Never have had a creatinine value greater than 5.

Numerator
1. **GPRA:** Patients with nephropathy assessment, defined as an estimated GFR with result and a quantitative urinary protein assessment during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.

Definitions

**Diabetes**
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.
Serum Creatinine
- Site-populated taxonomy DM AUDIT CREATININE TAX, or
- LOINC taxonomy

Note: CPT codes are not included since they do not store the result, which is used in this topic.

Nephropathy Assessment
Defined as any of the following:
- Estimated GFR with result during the report period, defined as any of the following:
  - Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
  - LOINC taxonomy
- Quantitative Urinary Protein Assessment during the report period, defined as any of the following:
  - CPT 82042, 82043, or 84156
  - LOINC taxonomy
  - Site-populated taxonomy BGP QUANT URINE PROTEIN

Note: Be sure to check with your laboratory supervisor that the names added to your taxonomy reflect quantitative test values.

- End Stage Renal Disease diagnosis/treatment defined as any of the following ever:
  - CPT 36145, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951-90970 or old codes 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327 (old codes), G0392 (old code), G0393 (old code), or S9339
  - POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.*
  - Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*

GPRA 2011 Description
During FY 2011, achieve the tentative target rate of 56.4% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

Patient List
List of diabetic patients with nephropathy assessment, if any.
2.1.7 Diabetic Retinopathy

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Diabetes Program/Dr. Mark Horton

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. All User Population patients diagnosed with diabetes prior to the report period.
2. **GPRA:** Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes (POV 250.00–250.93) prior to the report period, and at least 2 visits in the past year, and 2 DM-related visits ever. Key denominator for this and all diabetes-related topics below.
3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 or older at the beginning of the report period
   - Whose first ever DM diagnosis occurred prior to the report period
   - Who had at least 2 DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the report period
   - Never have had a creatinine value greater than 5

Numerators
1. **GPRA:** Patients receiving a qualified retinal evaluation* during the report period.
   
   **Note:** This numerator does not include refusals.
   - Patients receiving diabetic retinal exam during the report period.
   - Patients receiving other eye exams during the report period.
2. Patients who refused a diabetic retinal exam during the report period.

Definitions

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Serum Creatinine**
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy
Note: CPT codes are not included since they do not store the result, which is used in this topic.

Qualified Retinal Evaluation

- Diabetic retinal exam
- Other eye exam.

The following methods are qualifying for this measure:
  - Dilated retinal evaluation by an optometrist or ophthalmologist.
  - Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist.
  - Any photographic method formally validated to seven standard fields (ETDRS).

Diabetic Retinal Exam

Any of the following during the report period:
  - Exam Code 03 Diabetic Eye Exam (dilated retinal examination or validated photographic equivalent)
  - CPT 2022F Dilated retinal eye exam; 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist; 2026F Eye imaging validated to match the diagnosis from seven standard field stereoscopic photos; S0620 Routine ophthalmological examination including refraction; new patient; S0621 Routine ophthalmological examination including refraction; established patient; S3000 Diabetic indicator; retinal eye exam, dilated, bilateral.

Other Eye Exam

- Non-DNKA (did not keep appointment) visits to ophthalmology, optometry or validated teleophthalmology retinal evaluation clinics
- Non-DNKA visits to an optometrist or ophthalmologist. Searches for the following codes in the following order:
  - Clinic Codes A2, 17, 18, 64
  - Provider Code 24, 79, 08
  - CPT 67028, 67038, 67039, 67040, 92002, 92004, 92012, 92014
  - POV V72.0
  - Procedure 95.02.
Refusal of Diabetic Retinal Exam

- Refusal of Exam 03. Refusals are only counted if the patient did not have a diabetic retinal exam or other eye exam. If a patient had a diabetic retinal exam/other eye exam and a refusal, only the diabetic retinal exam/other eye exam will be counted.

GPRA 2011 Description:
During FY 2011, achieve the tentative target rate of 54.4% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

Patient List
List of diabetic patients with qualified retinal evaluation or refusal, if any.

2.1.8 Diabetic Access to Dental Services

No changes from Version 10.0 Patch 1

Owner/Contact
Dental Program/Dr. Patrick Blahut

National Reporting
Not reported nationally

Denominator
Active Diabetic patients; defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least 2 visits during the report period, and 2 DM-related visits ever.

Numerators
1. Patients with a documented dental visit during the report period.

   **Note:** This numerator does not include refusals.

2. Patients with documented dental exam refusal during the report period.

Definitions

**Diabetes**
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

**Documented Dental Visit**
For non-CHS visits, searches for any of the following:
- Dental ADA Code 0000 or 0190
- CPT Codes D0000 or D0190
- VExam Code 30
• POV V72.2.

For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

**Documented Refusal**

Non-CHS dental visit with refusal of any of the following:

• ADA Code 0000 or 0190
• CPT Code D0000 or D0190
• Exam 30.

Refusals are only counted if the patient did not have a documented dental visit.

**Patient List**

List of diabetic patients and documented dental visit or refusal, if any.

### 2.2 Dental Group

#### 2.2.1 Access to Dental Services

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Dental Program/Dr. Patrick Blahut

**National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominator**

**GPRA:** User Population patients, broken down by age groups: 0–5, 6–11, 12–19, 20–34, 35–44, 45–54, 55–74, 75 and older.

**Numerators**

1. **GPRA:** Patients with documented dental visit during the report period.
   
   **Note:** This numerator does not include refusals.

2. Patients with documented dental exam refusal during the report period.

**Definitions**

**Documented Dental Visit**

For non-CHS dental visits, searches for any of the following:

• Dental ADA Codes 0000 or 0190
• CPT Codes D0000 or D0190
• VExam 30
• POV V72.2

For CHS dental visits, searches for any visit with an ADA code. CHS visit defined as Type code of C in Visit file.

**Documented Refusal**
Non-CHS dental visit with refusal of any of the following:
• ADA Code 0000 or 0190
• CPT Code D0000 or D0190
• Exam 30

Refusals are only counted if the patient did not have a documented dental visit.

**GPRA 2011 Description**
During FY 2011, achieve the tentative target rate of 25.0% for the proportion of patients who receive dental services.

**Patient List**
List of patients with documented dental visit or refusal and date.

## 2.2.2 Dental Sealants

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Dental Program/Dr. Patrick Blahut

**National Reporting**
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominator**
No denominator. This measure is a total count only, not a percentage.

**Numerators**
1. **GPRA:** Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of dental sealants during the report period.

   **Note:** This numerator does not include refusals.

Age breakouts (HP 2010):
• <12 years
• 12-18 years
• >18 years

2. For patients meeting the User Population definition, the total number of documented sealant refusals during the report period.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**Dental Sealant**

- V Dental ADA Code 1351 or
- CPT Code D1351.

Only two sealants per tooth will be counted during the report period. Each tooth is identified by the data element Operative Site in RPMS. If both ADA and CPT codes are found on the same visit, only the ADA will be counted.

**Refusal of Dental Sealant**

Refusal of ADA Code 1351 or refusal of CPT Code D1351. Refusals are only counted if a patient did not have a sealant during the report period. If a patient had both a sealant and a refusal, only the sealant will be counted. If a patient has multiple refusals, only one refusal will be counted.

**GPRA 2011 Description**

During FY 2011, achieve the tentative target count of 279,328 sealants placed in AI/AN patients.

**Patient List**

List of patients who received or refused dental sealants during report period.

**2.2.3 Topical Fluoride**

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Dental Program/Dr. Patrick Blahut

**National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominator**

No denominator. This measure is a total count only, not a percentage.
Numerators

1. **GPRA**: Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of patients with at least one topical fluoride treatment during the report period.
   
   **Note**: This numerator does *not* include refusals.

2. For patients meeting the User Population definition, the total number of patients with a documented topical fluoride treatment refusal in past year.

Definitions

**Topical Fluoride Application**

- Dental ADA Codes 1201 (old code), 1203, 1204, 1205 (old code), 1206 or 5986
- CPT Codes D1203, D1204, D1206, or D5986
- POV V07.31

A maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

**Refusal of Topical Fluoride Application**

Refusal of any of the following:

- Dental ADA Code 1201 (old code), 1203, 1204, 1205 (old code), 1206 or 5986
- CPT Code D1203, D1204, D1206, or D5986

Refusals are only counted if a patient did not have a topical fluoride application during the report period. If a patient had both an application and a refusal, only the application will be counted. If a patient has multiple refusals, only one refusal will be counted.

**GPRA 2011 Description**

During FY 2011, achieve the tentative target count of 147,236 AI/AN patients who receive at least one topical fluoride application.

**Patient List**

List of patients who received or refused at least one topical fluoride application during report period.
2.3 Immunization Group

2.3.1 Adult Immunizations: Influenza

*Changes from Version 10.0 Patch 1, as noted.*

Owner/Contact
Epidemiology Program/Amy Groom, MPH

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. Active Clinical patients ages 50 or older.
   - Active Clinical patients ages 50–64
   - **GPRA:** Active Clinical patients ages 65 and older.
2. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least 2 visits during the report period, and 2 DM-related visits ever.

Numerators
1. **GPRA:** Patients with influenza vaccine documented during the report period or with a contraindication documented at any time before the end of the report period.

   **Note:** The only refusals included in this numerator are not medically indicated (NMI) refusals.

   - Patients with a contraindication or a documented NMI refusal.
2. Patients with documented influenza refusal during the report period.

Definitions

**Age**
Age of the patient is calculated at the beginning of the report period.

**Diabetes**
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

**Influenza Vaccine**
Any of the following during the report period:

  - Immunization/CVX codes:
- 88 Influenza Virus Vaccine, NOS; 15 Inf Virus Vac SV; 16 Inf Virus Vac WV; 111 Inf Virus Vac Intranasal; 135 Inf High Dose Seasonal; 140 Inf Virus Vac SV Preservative Free; 141 Inf Virus Vac SV
- POV V04.8 (old code), V04.81 not documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142, or V06.6 not documented with 90663, 90664, 90666-90668, 90470, G9141 or G9142
- CPT 90654-90662 (old code), G0008, G8108.

**Contraindication to Influenza Vaccine:**
Any of the following documented at any time before the end of the report period:
- Contraindication in the Immunization Package of Egg Allergy or Anaphylaxis
- PCC NMI Refusal

**Refusal of Influenza Vaccine:**
Any of the following documented during the report period:
- Refusal of immunization/CVX Codes 15, 16, 88, 111, 135, 140, or 141 as documented in PCC Refusal File (i.e., REF)
- In the Immunization Package as contraindication of Patient Refusal

**GPRA 2011 Description**
During FY 2011, achieve the tentative target rate of 63.5% for the proportion of non-institutionalized adults aged 65 years and older who receive an influenza immunization.

**Patient List**
List of patients >= 50 yrs or DM DX with Influenza code or refusal, if any.

### 2.3.2 Adult Immunizations: Pneumovax

**Changes from Version 10.0 Patch 1, as noted.**

**Owner/Contact**
Epidemiology Program/Amy Groom, MPH

**National Reporting**
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominators**
1. **GPRA:** Active Clinical patients ages 65 or older.
2. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least 2 visits during the report period, and 2 DM-related visits ever.

Numerator

1. **GPRA:** Patients with Pneumococcal vaccine or contraindication documented at any time before the end of the report period.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with a contraindication or a documented NMI refusal

2. **Patients with Pneumococcal vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumovax after the age of 65 or a dose of pneumovax in the past 5 years.**

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with a contraindication or a documented NMI refusal

3. Diabetic patients with pneumovax or contraindication documented ever and, if patient is older than 65 years, either a dose of pneumovax after the age of 65 or a dose of pneumovax in the past 5 years.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with a contraindication or a documented NMI refusal.

4. Patients with documented Pneumococcal refusal during the report period.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**Diabetes**

First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

**Pneumococcal Immunization**

Any of the following documented any time before the end of the report period:

- Immunization/CVX Codes 33 Pneumo Polysaccaride; 100 Pneumo Conjugate; 109 Pneumo NOS; 133 Pneumo Conjugate;
- POV V06.6, V03.82
- Procedure 99.55
- CPT 90669, 90670, 90732, G0009, G8115
Contraindication
Any of the following documented any time before the end of the report period:
- Contraindication in the Immunization Package of Anaphylaxis
- PCC NMI Refusal

Refusal
Any of the following documented during the report period:
- Immunization Codes 33, 100, 109 or 133, as documented in PCC Refusal File (i.e., REF)
- Immunization Package contraindication of Patient Refusal

GPRA 2011 Description
During FY 2011, achieve the tentative target rate of 86.1% for the proportion of adult patients age 65 years and older who receive a pneumococcal immunization.

Patient List
List of patients =>65 yrs or DM DX with pneumovax, contraindication, or refusal, if any.

2.3.3 H1N1 Immunization Status

DELETED: All performance measures and logic for H1N1 Immunization Status from the CRS Version 11.0 National GPRA Developmental Report. The H1N1 vaccine is now included in the Adult Influenza vaccine.

2.3.4 Childhood Immunizations

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Epidemiology Program/Amy Groom, MPH

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. Active Clinical patients ages 19–35 months at end of report period.
2. GPRA: User Population patients active in the Immunization Package who are 19–35 months at end of report period.

Note: Sites must be running the RPMS Immunization package for this denominator. Sites not running the package will have a value of zero for this denominator.
Numerators

1. Patients who have received the 4:3:1:3:3 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B), including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

2. Patients with documented 4:3:1:3:3 REF refusal in PCC or Parent or Patient refusal in the IZ program.

3. **GPRA:** Patients who have received the 4:3:1:3:3:1 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella), including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

4. Patients with documented 4:3:1:3:3:1 REF refusal in PCC or Parent or Patient refusal in the IZ program.

5. **GPRA Developmental:** Patients who have received the 4:3:1:3:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

6. Patients with documented 4:3:1:3:3:1:4 REF refusal in PCC or Parent or Patient refusal in the IZ program.

7. Patients who have received 4 doses of DTaP ever, including contraindications.

   **Note:** The only refusals included in this numerator are NMI refusals.

   - Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

8. Patients with documented DTaP REF refusal in PCC or Parent or Patient refusal in the IZ program.

9. Patients who have received three doses of Polio ever, including contraindications, and evidence of disease.

   **Note:** The only refusals included in this numerator are NMI refusals.
• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

10. Patients with documented Polio REF refusal in PCC or Parent or Patient refusal in the IZ program.
11. Patients who have received 1 dose of MMR ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

12. Patients with documented MMR REF refusal in PCC or Parent or Patient refusal in the IZ program.
13. Patients who have received 3 doses of HiB ever, including contraindications.

**Note:** The only refusals included in this numerator are NMI refusals.

• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

14. Patients with documented HiB REF refusal in PCC or Parent or Patient refusal in the IZ program.
15. Patients who have received 3 doses of Hepatitis B vaccine ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

16. Patients with documented Hepatitis B REF refusal in PCC or Parent or Patient refusal in the IZ program.
17. Patients who have received 1 dose of Varicella ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.

• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

18. Patients with documented Varicella REF refusal in PCC or Parent or Patient refusal in the IZ program.
19. Patients who have received 4 doses of Pneumococcal conjugate vaccine ever, including contraindications, and evidence of disease.

**Note:** The only refusals included in this numerator are NMI refusals.
• Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

20. Patients with documented Pneumococcal REF refusal in PCC or Parent or Patient refusal in the IZ program.

21. **Immunization Program Numerator**: Patients who have received the 4:3:1:3:3 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B), *not* including refusals, contraindications, and patients with evidence of disease.

22. **Immunization Program Numerator**: Patients who have received the 4:3:1:3:3:1 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, and 1 Varicella), *not* including refusals, contraindications, and patients with evidence of disease.

23. **Immunization Program Numerator**: Patients who have received the 4:3:1:3:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), *not* including refusals, contraindications, and patients with evidence of disease.

**Definitions**

**Patient Age**

Since the age of the patient is calculated at the beginning of the report period, the age range will be adjusted to 7–23 months at the beginning of the report period, which makes the patient between the ages of 19–35 months at the end of the report period.

**Timing of Doses**

Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

**Active Immunization Package Patients Denominator**

Same as User Population definition *except* includes only patients flagged as active in the Immunization Package.

**Note:** Only values for the current period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the previous year or baseline periods.

**Dosage and Types of Immunizations**

- 4 Doses of DTaP
  - 4 DTaP/DTP/Tdap
  - 1 DTaP/DTP/Tdap and 3 DT/Td
  - 1 DTaP/DTP/Tdap and 3 each of Diphtheria and Tetanus
  - 4 DT and 4 Acellular Pertussis
- 4 Td and 4 Acellular Pertussis
- 4 each of Diphtheria, Tetanus, and Acellular Pertussis

- **3 Doses of Polio**
  - 3 OPV
  - 3 IPV
  - Combination of OPV and IPV totaling 3 doses

- **1 Dose of MMR**
  - MMR
  - 1 M/R and 1 Mumps
  - 1 R/M and 1 Measles
  - 1 each of Measles, Mumps, and Rubella

- **3 doses of Hep B OR 2 doses IF documented with CPT 90743**

- **3 doses of HIB**

- **1 dose of Varicella**

- **4 doses of Pneumococcal**

**Refusal, Contraindication, and Evidence of Disease Information**

Except for the Immunization Program Numerators, NMI refusals, evidence of disease and contraindications for individual immunizations will also count toward meeting the definition, as defined below. Refusals will count toward meeting the definition for refusal numerators only.

**Note:** NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- Each immunization must be refused and documented separately. For example, if a patient refused Rubella only, then there must be an immunization, contraindication, or separate refusal for the Measles and Mumps immunizations.

- For immunizations where required number of doses is >1, only one refusal is necessary to be counted in the numerator. For example, if there is a single refusal for Hepatitis B, the patient will be included in the numerator.

- For immunizations where required number of doses is >1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

- Evidence of disease will be checked for at any time in the child's life (prior to the end of the report period).
To be counted in Subnumerator A, a patient must meet the numerator definition AND have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in Subnumerator A.

For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, all conditions shown below must be met:

- Each immunization must be refused and documented separately. For example, if a patient has an REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.
- Where the required number of doses is >1, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the 4 DTaP numerator, only one refusal is necessary to be counted in the refusal numerator.

**Refusal Definitions**

Parent/Patient Refusal in Immunization package or PCC Refusal type REF or NMI for IZ codes:

- DTaP: 20, 50, 106, 107, 110, 120, 130, 132
- DTP: 1, 22, 102
- Tdap: 115
- DT: 28
- Td: 9, 113
- Tetanus: 35, 112
- Acellular Pertussis: 11
- OPV: 2, 89
- IPV: 10, 89, 110, 120, 130, 132
- MMR: 3, 94
- M/R: 4
- R/M: 38
- Measles: 5
- Mumps: 7
- Rubella: 6
- HiB: 17, 22, 46-49; 50, 51, 102, 120, 132
- Hepatitis B: 8, 42-45, 51, 102, 104, 110, 132
- Varicella: 21, 94
- Pneumococcal: 33, 100, 109

**Immunization Definitions**

**Note:** In the definitions for all immunizations shown below, the Immunization Program Numerators will include only CVX and CPT codes.

- **DTaP IZ Definitions**
  - Immunization (CVX) Codes 20, 50, 106, 107, 110, 120, 130, 132
  - POV V06.1
  - CPT 90696, 90698, 90700, 90721, 90723
- **DTaP Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **DTP IZ Definitions**
  - Immunization (CVX) Codes 1, 22, 102
  - POV V06.1, V06.2, V06.3
  - CPT 90701, 90711 (old code), 90720
  - Procedure 99.39
- **DTP Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Td ap IZ Definitions**
  - Immunization (CVX) Code 115
  - CPT 90715
- **Tdap contraindication definition**
  - Immunization Package contraindication of Anaphylaxis

- **DT IZ Definitions**
  - Immunization (CVX) Code 28
  - POV V06.5
  - CPT 90702
- **DT Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Td IZ Definitions**
  - Immunization (CVX) Codes 9, 113
- POV V06.5
- CPT 90714, 90718

- **Td Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Diphtheria IZ Definitions**
  - POV V03.5
  - CPT 90719
  - Procedure 99.36

- **Diphtheria Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis

- **Tetanus Definitions**
  - Immunization (CVX) Codes 35, 112
  - POV V03.7
  - CPT 90703
  - Procedure 99.38

- **Tetanus Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

- **Acellular Pertussis Definitions**
  - Immunization (CVX) Code 11
  - POV V03.6
  - Procedure 99.37 (old code)

- **Acellular Pertussis Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

- **OPV Definitions**
  - Immunization (CVX) Codes 2, 89
  - CPT 90712

- **OPV Contraindication Definitions**
  - POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis.

- **IPV Definitions**
  - Immunization (CVX) Codes 10, 89, 110, 120, 130, 132
  - POV V04.0, V06.3
  - CPT 90696, 90698, 90711 (old code), 90713, 90723
  - Procedure 99.41
• **IPV Evidence of Disease Definitions**
  – POV or PCC Problem List (active or inactive) 730.70–730.79

• **IPV contraindication definition:**
  – Immunization Package contraindication of Anaphylaxis or Neomycin Allergy.

• **MMR Definitions**
  – Immunization (CVX) Codes 3, 94
  – POV V06.4
  – CPT 90707, 90710
  – Procedure 99.48

• **MMR Contraindication Definitions**
  – POV 279, V08, 042, 200–202, 203.0, 203.1, 203.8, 204–208
  – Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy.

• **M/R Definitions**
  – Immunization (CVX) Code 4
  – CPT 90708

• **M/R Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis.

• **R/M Definitions**
  – Immunization (CVX) Code 38
  – CPT 90709 (old code)

• **R/M Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis.

• **Measles Definitions**
  – Immunization (CVX) Code 5
  – POV V04.2
  – CPT 90705
  – Procedure 99.45

• **Measles Evidence of Disease Definition**
  – POV or PCC Problem List (active or inactive) 055*

• **Measles Contraindication Definition**
  – Immunization Package contraindication of Anaphylaxis.

• **Mumps Definitions**
- Immunization (CVX) Code 7
- POV V04.6
- CPT 90704
- Procedure 99.46
- **Mumps Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) 072*
- **Mumps Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.
- **Rubella Definitions**
  - Immunization (CVX) Code 6
  - POV V04.3
  - CPT 90706
  - Procedure 99.47
- **Rubella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 056*, 771.0
- **Rubella Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.
- **HiB Definitions**
  - Immunization (CVX) Codes: 17, 22, 46–49, 50, 51, 102, 120, I32
  - POV V03.81
  - CPT 90645-90648, 90698, 90720–90721, 90737 (old code), 90748
- **HiB Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.
- **Hepatitis B Definitions**
  - Immunization (CVX) Codes 8, 42–45, 51, 102, 104, 110, I32
  - CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021 (old code), Q3023 (old code)
- **Hepatitis B Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3.
- **Hepatitis B contraindication definition**
  - Immunization Package contraindication of Anaphylaxis.
- **Varicella Definitions**
  - Immunization (CVX) Codes 21, 94
  - POV V05.4
- CPT 90710, 90716

- **Varicella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 052*, 053*
  - Immunization Package contraindication of “Hx of Chicken Pox” or “Immune.”

- **Varicella Contraindication Definitions**
  - POV 279, V08, 042, 200–202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy.

- **Pneumococcal Definitions**
  - Immunization (CVX) Codes 33 Pneumo Polysaccaride; 100 Pneumo Conjugate; 109 Pneumo NOS, 133 Pneumo Conjugate
  - POV V06.6; V03.82
  - CPT 90669, 90670, 90732, G0009, G8115

- **Pneumococcal Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

**GPRA 2011 Description**

During FY 2011, achieve the tentative target rate of 81.0% for the proportion of AI/AN children ages 19–35 months who have received the recommended immunizations.

**Note:** In FY 2011, the GPRA measure changes to the 4:3:1:3:3:1:4 combination, which includes pneumococcal.

**Patient List**

List of patients 19–35 months with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

**Note:** Because age is calculated at the beginning of the report period, the patient's age on the list will be between 7–23 months

### 2.3.5 Adolescent immunizations

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Epidemiology Program/Dr. Scott Hamstra, Amy Groom, MPH
National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators
1. Active Clinical patients age 13.
2. Female Active Clinical patients age 13.
3. Active Clinical patients ages 13-17.
4. Female Active Clinical patients ages 13-17.

Numerators
1. Patients who have received the 2:3:1 combination (i.e., 2 MMR, 3 Hepatitis B, and 1 Varicella), including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
2. Patients who have received the 1:3:2:1 combination (i.e., 1 Td/Tdap, 3 Hepatitis B, 2 MMR, 1 Varicella), including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
3. Patients who have received 1 dose of Tdap/Td ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
4. Patients who have received 2 doses of MMR ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
5. Patients who have received 3 doses of Hepatitis B ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

6. Patients who have received 1 dose of Varicella ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

7. Patients who have received 1 dose of meningococcal ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

8. Patients who have received 3 doses of HPV ever, including refusals, contraindications, and evidence of disease.
   - Patients with documented REF refusal in PCC or Parent or Patient refusal in the IZ program.
   - Patients with either (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.

**Note:** Included for Female Active Clinical age 13 and Female Active Clinical ages 13–17 only.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**Timing of Doses**

Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

**Dosage and Types of Immunizations**

- One dose of Td or Tdap
- Two doses of MMR
• Two MMRs
• Two M/R and two Mumps
• Two R/M and two Measles
• Two each of Measles, Mumps, and Rubella
• Three doses of Hep B or 2 doses if documented with CPT 90743
• One dose of Varicella
• One dose of Meningococcal
• Three doses of HPV

Refusal, Contraindication, and Evidence of Disease Information
Refusals, evidence of disease, and contraindications for individual immunizations will also count toward meeting the definition, as defined below.

• Each immunization must be refused and documented separately. For example, if a patient refused Rubella only, then there must be an immunization, contraindication, or separate refusal for the Measles and Mumps immunizations.

• For immunizations where required number of doses is >1, only one refusal is necessary to be counted in the numerator. For example, if there is a single refusal for Hepatitis B, the patient will be included in the numerator.

• For immunizations where required number of doses is >1, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

• Evidence of disease will be checked for at any time in the child's life (prior to the end of the report period.)

• To be counted in subnumerator A, a patient must have a REF refusal in PCC or a Parent or Patient Refusal in the IZ program for any of the immunizations in the numerator. For example, if a patient refused Rubella only but had immunizations for Measles and Mumps, the patient would be included in subnumerator A.

• To be counted in sub-numerator B, a patient must have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in subnumerator B.

Refusal Definitions
• Parent/Patient Refusal in Immunization package
• PCC Refusal type REF
• NMI for IZ codes:
  – MMR: 3, 94
  – M/R: 4
  – R/M: 38
  – Measles: 5
  – Mumps: 7
  – Rubella: 6
  – Hepatitis B: 8, 42-45, 51, 102, 104, 110, 132
  – Varicella: 21, 94
  – Tdap: 115; Td: 9, 113
  – Meningococcal: 32, 108, 114, 136
  – HPV: 62, 118, 137

Immunization Definitions
• MMR
  – Immunization (CVX) Codes 3, 94
  – POV V06.4
  – CPT 90707, 90710
  – Procedure 99.48
• MMR Contraindication Definitions
  – POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  – Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy.
• M/R
  – Immunization (CVX) Code 4
  – CPT 90708
• M/R Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.
• R/M
  – Immunization (CVX) Code 38
  – CPT 90709 (old code)
• R/M Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.
• Measles
  – Immunization (CVX) Code 5
  – POV V04.2
• Measles Evidence of Disease Definition
  – POV or PCC Problem List (active or inactive) 055*

• Measles Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.

• Mumps
  – Immunization (CVX) Code 7
  – POV V04.6
  – CPT 90704
  – Procedure 99.46

• Mumps Evidence of Disease Definition
  – POV or PCC Problem List (active or inactive) 072*

• Mumps Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.

• Rubella
  – Immunization (CVX) Code 6
  – POV V04.3
  – CPT 90706
  – Procedure 99.47

• Rubella Evidence of Disease Definitions
  – POV or PCC Problem List (active or inactive) 056*, 771.0

• Rubella Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.

• Hepatitis B
  – Immunization (CVX) Codes 8, 42–45, 51, 102, 104, 110, 132
  – CPT 90636, 90723, 90731 (old code), 90740, 90743-90748, G0010, Q3021, Q3023

• Hepatitis B Evidence of Disease Definitions
  – POV or PCC Problem List (active or inactive) V02.61, 070.2, 070.3

• Hepatitis B Contraindication Definition
  – Immunization Package contraindication of Anaphylaxis.

• Varicella
  – Immunization (CVX) Codes 21, 94
- POV V05.4
- CPT 90710, 90716

- **Varicella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) 052*, 053*
  - Immunization Package contraindication of “Hx of Chicken Pox” or “Immune.”

- **Varicella Contraindication Definitions**
  - POV 279, V08, 042, 200-202, 203.0, 203.1, 203.8, 204–208
  - Immunization Package contraindication of Anaphylaxis, Immune Deficiency, Immune Deficient, or Neomycin Allergy.

- **Tdap**
  - Immunization (CVX) Code 115
  - CPT 90715

- **Tdap Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

- **Td**
  - Immunization (CVX) Code 9, 113
  - POV V06.5
  - CPT 90714, 90718

- **Td Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

- **Meningococcal**
  - CPT 90733, 90734

- **Meningococcal Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

- **HPV**
  - Immunization (CVX) Codes: 62, 118, 137
  - CPT 90649, 90650

- **HPV Contraindication Definition**
  - Immunization Package contraindication of Anaphylaxis.

**Patient List**

List of patients 13–17 with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had two Hep B, no IZ will be listed for Hep B.
2.4 Childhood Diseases Group

2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Dr. Scott Hamstra

**National Reporting**
Not reported nationally

**Denominator**
Active Clinical patients who were ages 3 months through 18 years who were diagnosed with an upper respiratory infection during the period 6 months (180 days) prior to the report period through the first 6 months of the report period.

**Numerator**
Patients who were not prescribed an antibiotic on or within three days after diagnosis. In this measure, appropriate treatment is not to receive an antibiotic.

**Definitions**

**Age**
Age is calculated as follows: Children 3 months as of 6 months (180 days) of the year prior to the report period to 18 years as of the first 6 months of the report period.

**Upper Respiratory Infection**
POV 460 or 465.*

**Outpatient Visit**
Service Category A, S, or O

**Antibiotic Medications:**
- Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS.
  - Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Ceftriaxone, Cefuroxime, Cephalaxin, Cephalexin, Cefpodoxime proxetil, Cefprozil, Ceftibuten, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ, Gatifloxacin, Levofloxacin, Lomefloxacin, Norfloxacin, Ofloxacin, Panitolin VK, Penicillin G, Sparfloxacin, Sulfa, Tetracycline, Trimethoprim, Trimethoprim-
Sulfamethoxazole. **Medications must not have a comment of RETURNED TO STOCK.**

- Procedure 99.21

- To be included in the denominator *all* of the following conditions must be met:
  - Patient’s diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit.
  - If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
  - Patient’s visit must *only* have a diagnosis of URI. If any other diagnosis exists, the visit will be excluded.
  - The patient did not have a new or refill prescription for antibiotics within 30 days prior to the URI visit date.
  - The patient did not have an active prescription for antibiotics as of the URI visit date. “Active” prescription defined as:
    - Rx Days Supply $\geq$ (URI Visit Date - Prescription Date)

If *there are multiple visits that meet the above criteria, the first visit will be used.*

**Patient List**

List of patients 3 months to 18 years with upper respiratory infection, with antibiotic prescription, if any.

### 2.4.2 Appropriate Testing for Children with Pharyngitis

**Changes from Version 10.0 Patch 1, as noted.**

**Owner/Contact**

Dr. Scott Hamstra

**National Reporting**

Not reported nationally

**Denominator**

Active Clinical patients who were ages 2–18 years who were diagnosed with pharyngitis and prescribed an antibiotic during the period 6 months (180 days) prior to the report period through the first 6 months of the report period.

**Numerator**

Patients who received a Group A strep test.
Definitions

Age
Age is calculated as follows: Children 2 years as of 6 months (180 days) of the year prior to the report period to 18 years as of the first 6 months of the report period.

Pharyngitis
POV 462, 463, or 034.0.

Outpatient Visit
Service Category A, S, or O.

Antibiotic Medications
• Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS
  – Medications are: Amoxicillin, Amox/Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil hydrate, Cefazolin, Cefdinir, Cefixime, Cefditoren, Cefibuten, Cefpodoxime proxetil, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Cephradine, Ciprofloxacin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Ery E-Succ/Sulfisoxazole, Gatifloxacin, Levofloxacin, Lomefloxacin, Loracarbef, Minocycline, Ofloxacin, Penicillin VK, Penicillin G, Sparfloxacin, Sulfisoxazole, Tetracycline, Trimethoprim, Trimethoprim-Sulfamethoxazol. Medications must not have a comment of RETURNED TO STOCK.
  • Procedure 99.21

Group A Streptococcus Test
• CPT 87430 (by enzyme immunoassay), 87650–87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture)
• Site-populated taxonomy BGP GROUP A STREP
• LOINC taxonomy.
• To be included in the denominator all of the following conditions must be met:
  – Patient's diagnosis of pharyngitis must have occurred at an outpatient visit.
  – If outpatient visit was to Clinic Code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as service category H, either on the same day or the next day with pharyngitis diagnosis.
  – Patient's visit must only have a diagnosis of pharyngitis. If any other diagnosis exists, the visit will be excluded.
– The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
– The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. “Active” prescription defined as:
  – Rx Days Supply >= (URI Visit Date - Prescription Date)
– The patient filled a prescription for antibiotics on or within three days after the pharyngitis visit.

If there are multiple visits that meet the above criteria, the first visit will be used.

- To be included in the numerator
  – A patient must have received a Group A Streptococcus test within the 7-day period beginning three days prior through three days after the Pharyngitis visit date.

Patient List
List of patients 2-18 years with pharyngitis and a Group A Strep test, if any.

2.5 Cancer Screen Group

2.5.1 Cancer Screening: Pap Smear Rates

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Carolyn Aoyama

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominator
GPRA: Female Active Clinical patients ages 21 through 64 without a documented history of hysterectomy. Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Numerators
1. GPRA: Patients with documented Pap smear in past three years in past year.
   
   Note: This numerator does not include refusals.

2. Patients with documented Pap smear refusal in past year.
Definitions

Age
Age of the patient is calculated at the beginning of the report period. Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.

Hysterectomy
Defined as any of the following ever:

- Procedure 68.4–68.8
- CPT 51925, 56308 (old code), 58150, 58152, 58200-58294, 58548, 58550–58554, 58570–58573, 58951, 58953–58954, 58956, 59135
- POV 618.5, V88.01, V88.03
- Women’s Health procedure called Hysterectomy

Pap Smear

- V Lab Pap Smear
- POV V67.01 Follow-up Vaginal Pap Smear, V76.2 Screen Mal Neop-Cervix, V72.31 Routine Gynecological Examination, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10–16, 795.19
- Procedure 91.46
- CPT 88141-88167, 88174-88175, G0123, G0124, G0141, G0143–G0145, G0147, G0148, P3000, P3001, Q0091
- Women’s Health: procedure called Pap Smear and where the result does NOT have “ERROR/DISREGARD”
- LOINC taxonomy
- Site-populated taxonomy BGP PAP SMEAR TAX

Refusal
- Refusal in past year of Lab Test Pap Smear

GPRA 2011 Description
During FY 2011, achieve the tentative target rate of 60.5% for the proportion of female patients ages 21 through 64 without a documented history of hysterectomy who have had a Pap screen within the previous three years.
Patient List
List of women 21–64 with documented Pap smear or refusal, if any.

2.5.2 Cancer Screening: Mammogram Rates

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Carolyn Aoyama

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. **GPRA**: Female Active Clinical patients ages 52 through 64, without a documented bilateral mastectomy or two separate unilateral mastectomies.
2. Female Active Clinical patients ages 42 and older without a documented history of bilateral mastectomy or two separate unilateral mastectomies.

Numerators
1. **GPRA**: All patients with documented mammogram in past two years.
   
   **Note**: This numerator does not include refusals.

2. Patients with documented mammogram refusal in past year.

Definitions

**Age**
Age of the patient is calculated at the beginning of the report period. For all denominators, patients must be at least the minimum age as of the beginning of the report period. For the 52–64 denominator, the patients must be less than 65 years of age as of the end of the report period.

**Bilateral Mastectomy**
- CPT 19300.50-19307.50 or 19300-19307 with modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, w/modifier of .50 or 09950 or
- ICD Operation codes 85.42; 85.44; 85.46; 85.48

**Unilateral Mastectomy**
Requires two separate occurrences for either CPT or procedure codes on two different dates of service.
- CPT 19300-19307, or old codes 19180, 19200, 19220, 19240 or
• Procedures 85.41, 85.43, 85.45, 85.47

**Mammogram**

• V Radiology or CPT 77053-77059, 76090 (old code), 76092 (old code), G0206; G0204, G0202

• POV V76.11 screening mammogram for high risk patient; V76.12 other screening mammogram; 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast

• Procedure 87.36 Xerography of breast, 87.37 Other Mammography

• Women’s Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat; and where the mammogram result does not have "ERROR/DISREGARD".

**Refusal Mammogram**

Any of the following in the past year:

• V Radiology MAMMOGRAM for CPT 77053-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202.

**GPRA 2011 Description**

During FY 2011, achieve the tentative target rate of 50.9% for the proportion of female patients ages 52 through 64 who have had mammography screening within the last 2 years.

**Patient List**

List of women 42+ with mammogram/refusal, if any.

---

### 2.5.3 Colorectal Cancer Screening

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Epidemiology Program/Dr. Nathaniel Cobb

**National Reporting**

NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

**Denominator**

**GPRA**: Active Clinical patients ages 51–80 without a documented history of colorectal cancer or total colectomy, broken out by gender.
Numerators

1. **GPRA:** Patients who have had any CRC colorectal screening, defined as any of the following:
   - Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during the report period;
   - Flexible sigmoidoscopy or double contrast barium enema in the past five years;
   - Colonoscopy in the past 10 years

**Note:** This numerator does not include refusals.

2. Patients with documented CRC screening refusal in the past year.
3. Patients with FOBT or FIT during the report period.
4. Patients with a flexible sigmoidoscopy or double contrast barium enema in the past 5 years or a colonoscopy in the past 10 years.
5. Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.
6. Patients with a flexible sigmoidoscopy and double contrast barium enema in the past 5 years or a colonoscopy in the past 10 years.

Definitions

**Age**

Age is calculated at the beginning of the report period.

**Denominator Exclusions**

Any diagnosis ever of one of the following:

- **Colorectal Cancer**
  - POV 153.*, 154.0, 154.1, 197.5, V10.05
  - CPT G0213–G0215 (old codes), G0231 (old code)
- **Total Colectomy**
  - CPT 44150–44151, 44152 (old code), 44153 (old code), 44155–44158, 44210–44212
  - Procedure 45.8 (old code)

**Colorectal Cancer Screening**

The most recent of any of the following during applicable time frames (changed to look at most recent screening):

- **FOBT or FIT**
  - CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code)
- LOINC taxonomy
- Site-populated taxonomy BGP GPRA FOB TESTS

**Flexible Sigmoidoscopy**
- Procedure 45.24
- CPT 45330–45345, G0104

**Double Contrast Barium Enema**
- CPT or V Radiology 74280, G0106, G0120

**Colonoscopy**
- POV V76.51 Colon screening
- Procedure 45.22, 45.23, 45.25, 45.42, 45.43
- CPT 44388–44394, 44397, 45355, 45378–45387, 45391, 45392, G0105, G0121

**Screening Refusals in Past Year**

**FOBT or FIT**
- Refusal of V Lab Fecal Occult Blood test or
- CPT code 82270, 82274, 89205 (old code), G0107 (old code), G0328, or G0394 (old code)

**Flexible Sigmoidoscopy**
- Refusal of Procedure 45.24 or
- CPT 45330-45345, G0104

**Double Contrast Barium Enema**
- Refusal of V Radiology CPT 74280, G0106, G0120

**Colonoscopy**
- Refusal of Procedure 45.22, 45.23, 45.25, 45.42, 45.43 or
- CPT 44388–44394, 44397, 45355, 45378–45387, 45391, 45392, G0105, or G0121

**GPRA 2011 Description**

During FY 2011, achieve the tentative target rate of *39.8%* for the proportion of clinically appropriate patients ages 51–80 who have received colorectal screening.

**Patient List**

List of patients 51–80 with CRC screening or refusal, if any.
2.5.4 Comprehensive Cancer Screening

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Epidemiology Program/ Dr. Nathaniel Cobb, Carolyn Aoyama

**National Reporting**
NATIONAL (included in IHS Performance Report; *not* reported to OMB and Congress)

**Denominators**
1. **GPRA Developmental:** Active Clinical patients ages 21–80 who are eligible for cervical cancer, breast cancer, and/or colorectal cancer screening.
   - Active Clinical female patients ages 21–80.
   - Active Clinical male patients ages 51–80.

**Numerators**
1. **GPRA Developmental:** Patients who have had all screenings for which they are eligible.
2. Female patients with cervical cancer, breast cancer, and/or colorectal cancer screening.
3. Male patients with colorectal cancer screening.

**Definitions**

**Age**
Age of the patient is calculated at the beginning of the report period.

**Cervical Cancer Screening**
To be eligible for this screening:
- Patients must be female Active Clinical ages 21 through 64 and not have a documented history of hysterectomy.
- Patients must be at least 21 years of age at the beginning of the report period and less than 65 years of age as of the end of the report period.
- To be counted as having the screening, the patient must have had a Pap Smear documented in the past 3 years.

**Hysterectomy**
Any of the following ever:
- Procedure 68.4–68.8
- CPT 51925, 56308 (old code), 58150, 58152, 58200–58294, 58548, 58550–58554, 58570–58573, 58951, 58953–58954, 58956, 59135
- POV 618.5, V88.01, V88.03
- Women’s Health procedure called Hysterectomy

**Pap Smear**
- V Lab Pap Smear
- POV V67.01 Follow-up Vaginal Pap Smear, V76.2 Screen Mal Neop-Cervix, V72.31 Routine Gynecological Examination, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, V72.3 Gynecological Examination, Pap Cervical Smear as Part of General Gynecological Exam, Pelvic Exam (annual) (periodic) (old code, to be counted for visits prior to 10/1/04 only), V76.47 Vaginal Pap Smear for Post-Hysterectomy Patients, 795.0*, 795.10–16, 795.19

- Procedure 91.46
- CPT 88141-88167, 88174–88175, G0123, G0124, G0141, G0143–G0145, G0147, G0148, P3000, P3001, Q0091
- Women’s Health: Procedure called Pap Smear and where the result does NOT have “ERROR/DISREGARD”
- LOINC taxonomy
- Site-populated taxonomy BGP PAP SMEAR TAX

**Breast Cancer Screening**
To be eligible for this screening
- Patients must be female Active Clinical ages 52 through 64 and not have a documented history ever of bilateral mastectomy or two separate unilateral mastectomies
- Patients must be at least age 52 as of the beginning of the report period and must be less than 65 years of age as of the end of the report period
- To be counted as having the screening, the patient must have had a Mammogram documented in the past two years

**Bilateral Mastectomy**
Any of the following ever:
- CPT 19300.50–19307.50 or 19300–19307 with modifier 09950 (.50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, with modifier of .50 or 09950
- ICD Operation codes 85.42; 85.44; 85.46; 85.48
Unilateral Mastectomy

Must have two separate occurrences for either CPT or procedure codes on two different dates of service:

- CPT 19300–19307, or old codes 19180, 19200, 19220, 19240
- ICD Operation codes 85.41, 85.43, 85.45, 85.47

Screening Mammogram

- V Radiology or CPT 77053-77059, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202
- POV V76.11 screening mammogram for high risk patient; V76.12 other screening mammogram; 793.80 Abnormal mammogram, unspecified; 793.81 Mammographic microcalcification; 793.89 Other abnormal findings on radiological exam of breast
- Procedure 87.36 Xerography of breast, 87.37 Other Mammography
- Women’s Health: Mammogram Screening, Mammogram Dx Bilat, Mammogram Dx Unilat and where the mammogram result does not have "ERROR/DISREGARD"

Colorectal Cancer Screening

To be eligible for this screening:

- Patients must be Active Clinical ages 51–80 and not have a documented history ever of colorectal cancer or total colectomy;
- To be counted as having the screening, patients must have had any of the following:
  - FOBT or FIT during the report period
  - Flexible sigmoidoscopy or double contrast barium enema in the past 5 years
  - Colonoscopy in the past 10 years

Colorectal Cancer

- POV 153.*, 154.0, 154.1, 197.5, V10.05
- CPT G0213-G0215 (old codes), G0231 (old code)

Total Colectomy

- Procedure 45.8 (old code)
- CPT 44150-44151, 44152 (old code), 44153 (old code), 44155-44158, 44210-44212
FOBT or FIT
- **POV V76.51 Colon screening**
  - CPT 82270, 82274, 89205 (old code), G0328, G0394 (old code)
  - LOINC taxonomy
  - Site-populated taxonomy BGP GPRA FOB TESTS

Flexible Sigmoidoscopy
- Procedure 45.24
- CPT 45330–45345, G0104

*Double Contrast Barium Enema*
- CPT or VRad 74280, G0106, G0120

Colonoscopy
- **POV V76.51 Colon screening**
  - Procedure 45.22, 45.23, 45.25, 45.42, 45.43
  - CPT 44388–44394, 44397, 45355, 45378-45387, 45391, 45392, G0105, G0121

Patient List
List of patients 21–80 with comprehensive cancer screening, if any.

2.5.5 Tobacco Use and Exposure Assessment

*Changes from Version 10.0 Patch 1, as noted.*

Owner/Contact
Mary Wachacha and Chris Lamer, PharmD/Epidemiology Program, Dr. Nat Cobb

National Reporting
NATIONAL (included in National GPRA and PART Report; not reported to OMB and Congress)

Denominators
1. Active Clinical patients ages 5 and older, broken down by gender and age groups: 5–13, 14–17, 18–24, 25–44, 45–64, 65 and older (HP 2010).
2. Pregnant female User Population patients with no documented miscarriage or abortion.

Numerators
1. Patients screened for tobacco use during the report period (during the past 20 months for pregnant female patients denominator).
2. Patients identified during the report period (during the past 20 months for pregnant female patients denominator) as current tobacco users.
   - Current smokers
   - Current smokeless tobacco users

3. Patients exposed to environmental tobacco smoke (ETS) during the report period (during the past 20 months for pregnant female patients denominator).

Definitions

Age
Age calculated at beginning of report period

Pregnancy
At least 2 visits with POV: V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.* during the past 20 months. **Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.** If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. An additional eight months is included for patients who were pregnant during the report period but who had their tobacco assessment prior to that.

Miscarriage
- Occurring after the second pregnancy POV and during the past 20 months
  - POV 630, 631, 632, 633*, 634*
  - CPT 59812, 59820, 59821, 59830

Abortion
- Occurring after the second pregnancy POV and during the past 20 months
  - POV 635*, 636*, 637*
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  - Procedure 69.01, 69.51, 74.91, 96.49

Tobacco Screening
- Time frame for pregnant female patients is the past 20 months
- Any Health Factor for category Tobacco, **TOBACCO (SMOKING)**, **TOBACCO (SMOKELESS – CHEWING/DIP)**, or **TOBACCO (EXPOSURE)**
• POV or Current PCC Problem List 305.1, 305.1* (old codes), 649.00–649.04, or V15.82 (tobacco-related diagnosis)

• Dental Code 1320

• Patient Education codes containing “TO-”, “-TO”, “-SHS,” 305.1, 305.1* (old codes), 649.00–649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402, or G8453

• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), or 1036F (Current Tobacco Non-User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed), G8455 (Current Tobacco Smoker), G8456 (Current Smokeless Tobacco User), G8457 (Tobacco Non-User), G8402 (Tobacco (Smoke) Use Cessation Intervention, Counseling), or G8453 (Tobacco Use Cessation Intervention, Counseling)

Tobacco Users

• Time frame for pregnant female patients is the past 20 months

• Health Factors: Current Smoker, Current Smokeless, Current Smoker and Smokeless, Cessation-Smoker, Cessation-Smokeless, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day

• POV 305.1, 305.10–305.12 (old codes), or 649.00–649.04

• CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455, G8456, G8402, or G8453

Current Smokers

• Time frame for pregnant female patients is the past 20 months

• Health Factors: Current Smoker, Current Smoker and Smokeless, Cessation-Smoker, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day

• POV 305.1, 305.10–305.12 (old codes), or 649.00–649.04

• CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, G8455, G8402, or G8453

Current Smokeless

• Time frame for pregnant female patients is the past 20 months

• Health Factors: Current Smokeless, Current Smoker and Smokeless, or Cessation-Smokeless

• CPT 1035F or G8456
ETS
- Time frame for pregnant female patients is the past 20 months
- Health Factors: Smoker in Home, Exposure to ETS

Patient List
List of patients 5 and older with no documented tobacco screening.

2.5.6 Tobacco Cessation

Changes from Version 10.0 Patch 1, as noted.

Note: The GPRA Developmental report contains a set of denominators, numerators, and logic that may become the GPRA logic in a future GPRA year. This logic is included only in the GPRA Developmental report.

Owner/Contact
Mary Wachacha and Chris Lamer, PharmD/Epidemiology Program, Dr. Nat Cobb

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominator
1. **GPRA**: Active Clinical patients identified as current tobacco users prior to the report period, broken down by gender and age groups: <12, 12-17, 18 and older.

Numerator
1. **GPRA**: Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid during the report period.

Note: This numerator does not include refusals.

2. Patients who refused tobacco cessation counseling during the report period.
3. Patients identified during the report period as having quit their tobacco use.
4. Patients who have received tobacco cessation counseling, received a prescription for a smoking cessation aid, or who quit their tobacco use during the report period.

Note: This numerator does not include refusals.

Definitions

**Age**
Age is calculated at the beginning of the report period.
**Current Tobacco Users**

Any of the following documented prior to the report period:

- Health Factors (looks at the last documented *in the Tobacco, TOBACCO (SMOKING) and TOBACCO (SMOKELESS – CHEWING/DIP) categories*): Current Smoker, Current Smokeless, Current Smoker and Smokeless, Cessation-Smoker, Cessation-Smokeless, Current Smoker, status unknown, Current smoker, every day, or Current smoker, some day

- Last documented Tobacco-related Diagnoses (POV or active Problem List) 305.1, 305.10–305.12 (old codes), or 649.00–649.04

- Last documented CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1035F, G8455, G8456, G8402 or G8453

If any of the above are found, the patient is considered a tobacco user.

**Tobacco Cessation Counseling**

Any of the following documented during the report period:

- Patient Education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, **D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402 or G8453**

- Clinic Code 94

- Dental Code 1320

- CPT code D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, 4000F, G8402 or G8453

**Prescription for Tobacco Cessation Aid**

Any of the following:

- Medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy

- Any medication with name containing “NICOTINE PATCH,” “NICOTINE POLACRILEX,” “NICOTINE INHALER,” or “NICOTINE NASAL SPRAY”

- **CPT 4001F**

**Quit Tobacco Use**

Any of the following documented during the report period:

- POV or Current Active Problem List diagnosis code 305.13 Tobacco use in remission (old code) or V15.82

- Health Factors Previous documented during the report period (looks at the last documented health factor): Previous Smoker, Previous Smokeless, **Previous (Former) Smoker, Previous (Former) Smokeless**
GPRA 2011 Description
During FY 2011, achieve the tentative target rate of 25.7% for the proportion of tobacco-using patients who receive tobacco cessation intervention.

Patient List
List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.

2.6 Behavioral Health Group

2.6.1 Alcohol Screening (Fetal Alcohol Syndrome [FAS] Prevention)

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Wilbur Woodis and Dr. Peter Stuart

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominator
1. GPRA: Female Active Clinical patients ages 15 to 44 (child-bearing age).

Numerators
1. GPRA: Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, received alcohol-related patient education, during the report period.

Note: This numerator does not include refusals.

- Patients with alcohol screening during the report period.
- Patients with alcohol-related diagnosis or procedure during the report period.
- Patients with alcohol-related patient education during the report period.
- Patients with documented refusal in past year.

2. Patients with documented alcohol screening refusal in past year.

Definitions

Age
Age is calculated at beginning of report period.

Alcohol Screening
Any of the following during the report period:
- PCC Exam Code 35
• Any CAGE Alcohol Health Factor
• Screening Diagnosis V11.3; V79.1, or BHS Problem Code 29.1
• CPT 99408, 99409, G0396, G0397, H0049, H0050
• V Measurement in PCC or BH of AUDT, AUDC, or CRFT

**Alcohol-Related Diagnosis or Procedure**
Any of the following during the report period:
• Alcohol-related Diagnosis
  – POV, Current PCC or BHS Problem List 303.*, 305.0*; 291.*; 357.5*
  – BHS POV 10, 27, 29
• Alcohol-related Procedure
  – Procedure 94.46, 94.53, 94.61–94.63, 94.67–94.69

**Alcohol-Related Patient Education**
Any of the following during the report period:
• All Patient Education codes containing “AOD-” or “-AOD”, “CD-” or “-CD” (old codes), or V11.3, V79.1, 303.*, 305.0*, 291.*, 357.5*, **99408, 99409, G0396, G0397, H0049, or H0050.**

**Refusal of Alcohol Screening:**
Refusal of PCC Exam Code 35

**GPRA 2011 Description**
During FY 2011, achieve the tentative target rate of **56.1%** for the proportion of female patients ages 15 to 44 who receive screening for alcohol use.

**Patient List**
List of female patients with no documented alcohol screening or refusal.

### 2.6.2 Alcohol Screening and Brief Intervention (ASBI) in the ER

**Changes from Version 10.0 Patch 1, as noted.**

**Owner/Contact**
Drs. David Boyd and Peter Stuart

**National Reporting**
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)
Denominators

1. Number of visits for Active Clinical patients age 15–34 seen in the ER for injury during the report period. Broken out by gender and age groups of 15–24 and 25–34.

2. Number of visits for Active Clinical patients age 15–34 seen in the ER for injury and screened positive for hazardous alcohol use during the report period. Broken out by gender and age groups of 15–24 and 25–34.

Numerators

1. Number of visits where patients were screened in the Emergency Room (ER) for hazardous alcohol use.
   • Number of visits where patients were screened positive (also used as denominator #2)

1. Number of visits where patients were provided a brief negotiated interview (BNI) at or within 7 days of the ER visit (used only with denominator #2).
   • Number of visits where patients were provided a BNI at the ER visit.
   • Number of visits where patients were provided a BNI not at the ER visit but within 7 days of the ER visit.

Definitions

Age

Age of the patient is calculated as of the beginning of the report period.

ER Visit

Clinic Code 30

Injury

Primary or secondary POV 800.0–999.9 or E800.0–E989

Denominator and Numerator Logic

If a patient has multiple ER visits for injury during the report period, each visit will be counted in the denominator. For the screening numerator, each ER visit with injury at which the patient was screened for hazardous alcohol use will be counted. For the positive alcohol use screen numerator, each ER visit with injury at which the patient screened positive for hazardous alcohol use will be counted. For the BNI numerators, each visit where the patient was either provided a BNI at the ER or within 7 days of the ER visit will be counted.

An example of this logic is shown in the following table.
ER Visit with Injury

<table>
<thead>
<tr>
<th></th>
<th>Denom Count</th>
<th>Scm Count</th>
<th>Post Scm Count</th>
<th>BNI Num Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Doe, 07/17/09, Screened Positive at ER, BNI at ER</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>John Doe, 09/01/09, Screened Positive at ER, No BNI</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>John Doe, 11/15/09, No Screen</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Counts:</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

**ER Screening for Hazardous Alcohol Use**

Any of the following conducted during the ER visit:

- PCC Exam Code 35
- Any Alcohol Health Factor (i.e., CAGE)
- POV V79.1 Screening for Alcoholism
- CPT G0396, G0397, H0049, 99408, 99409
- Measurement in PCC of AUDT, AUDC, CRFT

**Positive Screen for Hazardous Alcohol Use**

Any of the following for the screening performed at the ER visit:

- Exam Code 35 Alcohol Screening result of Positive
- Health factor of CAGE result of 1/4, 2/4, 3/4 or 4/4
- CPT G0396, G0397, 99408, or 99409
- AUDT result of =>8, AUDC result of =>4 for men and =>3 for women, CRFT result of 2-6

**BNI**

Any of the following documented at the ER visit or within 7 days of the ER visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:

- CPT G0396, G0397, H0050, 99408, or 99409
- Patient education code containing AOD-BNI, G0396, G0397, H0050, 99408, or 99409.

**Patient List**

List of patients seen in the ER for an injury who were screened for hazardous alcohol use, with results of screen and BNI, if any.
2.6.3 Intimate Partner (Domestic) Violence Screening

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Denise Grenier, LCSW and Dr. Peter Stuart

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. Female Active Clinical patients ages 13 and older at beginning of report period.
2. GPRA: Female Active Clinical patients ages 15–40.

Numerators
1. GPRA: Patients screened for or diagnosed with intimate partner violence/domestic violence (IPV/DV) during the report period.

   Note: This numerator does not include refusals.

   • Patients with documented IPV/DV exam.
   • Patients with IPV/DV related diagnosis.
   • Patients provided with IPV/DV patient education or counseling.

2. Patients with documented refusal in past year of an IPV/DV exam or IPV/DV-related education.

Definitions

Age
Age is calculated at beginning of the report period.

IPV/DV Screening
Defined as at least one of the following:

• IPV/DV Screening
  – PCC Exam Code 34
  – BHS IPV/DV exam

• IPV/DV Related Diagnosis
  – POV, Current PCC or BHS Problem List 995.80-83, 995.85, V15.41, V15.42, V15.49
  – BHS POV 43.*, 44.*

• IPV/DV Patient Education
– Patient Education codes containing “DV-” or “-DV”, 995.80-83, 995.85, V15.41, V15.42, or V15.49

- **IPV/DV Counseling**
  – POV V61.11

**Refusals**
Defined as:
- Any PCC refusal in past year with Exam Code 34 or BHS refusal in past year of IPV/DV exam
- Any refusal in past year with Patient Education codes containing "DV-" or “-DV”

**GPRA 2011 Description**
During FY 2011, achieve the tentative target rate of 57.3% for the proportion of female patients ages 15 to 40 who receive screening for domestic violence.

**Patient List**
List of female patients 13 and older not screened for IPV/DV.

### 2.6.4 Depression Screening

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Denise Grenier, LCSW and Drs. David Sprenger and Peter Stuart

**National Reporting**
NATIONAL (included in National and PART GPRA Report; reported to OMB and Congress)

**Denominators**
1. **GPRA:** Active Clinical patients ages 18 and older, broken out by gender.
   - Active Clinical patients ages 65 and older, broken out by gender
2. Active Diabetes patients, defined as: all Active Clinical patients diagnosed with diabetes prior to the report period, *and* at least two visits during the report period, *and* two DM-related visits ever, broken out by gender.
3. Active ischemic heart disease (IHD) patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, *and* at least two visits during the report period, *and* two IHD-related visits ever, broken out by gender.

**Numerators**
1. **GPRA:** Patients screened for depression or diagnosed with mood disorder at any time during the report period.
Note: This numerator does not include refusals.

- Patients screened for depression during the report period.
- Patients with a diagnosis of a mood disorder during the report period.

2. Patients with documented depression screening refusal in past year.
3. Patients with depression-related education or refusal of education in past year.

Note: Depression-related patient education does not count toward the GPRA numerator and is included as a separate numerator only.

Definitions

Age
Age is calculated at beginning of the report period.

Diabetes
First DM Purpose of Visit 250.00–250.93 recorded in the V POV file prior to the report period.

IHD
- POV 410.0–412.*, 414.0–414.9, 428.*, 429.2

Depression Screening
Any of the following:
- Exam Code 36
- POV V79.0
- BHS Problem Code 14.1 (screening for depression)
- V Measurement in PCC or BH of PHQ2 or PHQ9

Mood Disorders
At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.
- These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 or BHS POV 14 or 15

Screening Refusal
Any PCC refusal in past year with Exam Code 36.
**Depression-Related Patient Education or Refusal**

Any of the following during the report period:

- Patient education codes containing “DEP-” (depression), 296.2* or 296.3*, “BH-” (behavioral and social health), 290-319, 995.5*, or 995.80–995.85, “SB-” (suicidal behavior) or 300.9, or “PDEP-” (postpartum depression) or 648.44

- Refusal of patient education codes containing “DEP-”, “BH-”, “SB-” or “PDEP-”

**GPRA 2011 Description**

During FY 2011, achieve the tentative target rate of 56.3% for the proportion of adults ages 18 and older who receive annual screening for depression.

**Patient List**

List of patients not screened for depression/diagnosed with mood disorder.

---

**2.6.5 Antidepressant Medication Management**

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Denise Grenier, LCSW and Dr. David Sprenger

**National Reporting**

Not reported nationally

**Denominator**

1. As of the 120th day of the report period, Active Clinical patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

2. As of the 120th day of the Report period, User Population patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

**Numerators**

1. Optimal Practitioner Contacts: Patients with at least three mental health visits with a non-mental health or mental health provider within 12 weeks (84 days) after diagnosis, two of which must be face-to-face visits and one of which must be with a prescribing provider.

2. Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).
3. Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions/refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).

Definitions

Age
Age is calculated at the beginning of the report period.

Major Depression
POV 296.2*, 296.3*, 298.0, 300.4, 309.1, 311. The Index Episode Start Date is date of the patient’s earliest visit during this period. For inpatient visits, the discharge date will be used.

Index Episode Start Date
The date of the patient’s earliest visit during this period. For inpatient visits, the discharge date will be used.

Antidepressant Medications
Medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS.

- Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinepherine reuptake inhibitors (SNRI), and other antidepressants. Medications must not have a comment of RETURNED TO STOCK.

To be included in the denominator, patient must meet both of the following conditions:

- One of the following from the 121st day of the year prior to the report period to the 120th day of the report period:
  - One visit in any setting with major depression DX (see list of codes) as primary POV
  - Two outpatients visits occurring on different dates of service with secondary POV of major depression
  - An inpatient visit with secondary POV of major depression

For example, if report period is July 1, 2010–June 30, 2011, patient must have one of the three scenarios above during November 01, 2009–October 29, 2010.

- Filled a prescription for an antidepressant medication (see list of medications below) within 30 days before the Index Episode Start Date or 14 days on or after that date. In V Medication, Date Discontinued must not be equal to the prescription, (i.e., visit date). The Index Prescription Date is the date of earliest prescription for antidepressant medication filled during that time period.
Denominator Exclusions

- Patients who have had any diagnosis of depression within the previous 120 days (4 months) of the Index Episode Start Date. The POVs to be checked for prior depressive episodes are more comprehensive and include the following:
  - POV 296.2*-296.9*, 298.0, 300.4, 309.0, 309.1, 309.28, 311
- Patients who had a new or refill prescription for antidepressant medication (see list of medications below) within 90 days (3 months) prior to the Index Prescription Date are excluded as they do not represent new treatment episodes.
- Patients who had an acute mental health or substance abuse inpatient stay during the 245 days after the Index Episode Start Date treatment period. Acute mental health stays are defined as Service Category of H and primary POV 290*, 293*–302*, 306*-316*. Substance abuse inpatient stays are defined as Service Category of H and primary POV 291*–292*, 303*–305* or primary POV 960*-979* and secondary POV of 291*–292*, 303*–305*.

Optimal Practitioner Contacts Numerator

Patient must have one of the following:

- Three face-to-face follow-up outpatient, non-ER visits (clinic code not equal to 30) or intermediate treatment with either a non-mental health or mental health provider within 84 days after the Index Episode Start Date, or
- Two face-to-face outpatient, non-ER visits (clinic code not equal to 30) and one telephone visit (Service Category T) with either a non-mental health or mental health provider within 84 days after the Index Episode Start Date. For either option, one of the visits must be to a prescribing provider, defined as provider codes 00, 08, 11, 16–18, 21, 24–25, 30, 33, 41, 44–45, 47, 49, 64, 67–68, 70–83, 85–86, A1, A9, or B1–B6.

Note: If patient was diagnosed with two secondary diagnoses of depression, the second visit may be counted toward the numerator.

Outpatient Mental Health Provider Visits

- BHS or PCC visit with primary provider code of 06, 12, 19, 48, 49, 50, 62, 63, 81, or 92–96, and
- Service category A, S, or O, and
  - POV 290*, 293*–302*, 306*-316*, or
- Service category of A, S, or O and
  - Location of Encounter = Home (as designated in Site Parameters) or
  - Clinic code = 11, or
- Service category of T

**Outpatient Non-Mental Health Provider Visits**
Defined as BHS or PCC visits with:
- Service category A, S, or O, and
- Service category A, S, O, or T or
  - Location of Encounter = Home (as designated in Site Parameters) or
  - Clinic Code 11 and
  - POV 290*, 293*-302*, 306*-316*, or
- Service category A, S, or O, and
  - CPT 99384-99387, 99394–99397, 99401–99404
  - POV 290*, 293*-302*, 306*-316*

**Effective Acute Phase Treatment Numerator**
For all antidepressant medication prescriptions filled (see list of medications below) within 114 days of the Index Prescription Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Prescription Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 30 days or if the patient does not have 84 treatment days within the 114 day timeframe; the patient is not included in the numerator.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date, (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

**Example of Patient Included in Numerator:**
- 1st RX is Index Rx Date: 11/1/2010, # Days Prescribed=30
  - Rx covers patient through 12/1/2010
- 2nd RX: 12/15/2010, # Days Prescribed=30
Gap #1 = (12/15/2010–12/1/2010) = 14 days
Rx covers patient through 1/14/2011

3rd RX: 1/10/2011, # Days Prescribed=30
No gap days.
Rx covers patient through 2/13/2011
Index Rx Date 11/1/2010 + 114 days = 2/23/2011

Patient’s 84th treatment day occurs on 2/7/2011, which is <= 2/23/2011
and # gap days of 14 is less than 30.

Example of Patient Not Included in Numerator:

1st Rx is Index Rx Date: 11/1/2010, # Days Prescribed=30
Rx covers patient through 12/1/2010

2nd Rx: 12/15/2010, # Days Prescribed=30
Gap #1 = (12/15/2010–12/1/2010) = 14 days
Rx covers patient through 1/14/2011

3rd Rx: 2/01/2011, # Days Prescribed=30
Gap #2 = (2/01/2011–1/14/2011) = 18, total # gap days = 32, so patient is
not included in the numerator.

Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see list of medications above)
filled within 231 days of the Index Prescription Date, CRS counts the days
prescribed (i.e., treatment days) (from V Medication) from the Index Prescription
Date until a total of 180 treatment days has been established. If the patient had a
total gap exceeding 51 days or if the patient does not have 180 treatment days
within the 231 day timeframe, the patient is not included in the numerator.

Note: If the medication was started and then discontinued, CRS will
recalculate the # Days Prescribed by subtracting the prescription date
(i.e., visit date) from the V Medication Discontinued Date. For
example: Rx Date=11/15/2011, Discontinued Date=11/19/2011,
Recalculated # Days Prescribed=4.

Patient List

List of patients with new depression DX and optimal practitioner contact (OPC),
acute phase treatment (APT) and continuation phase treatment (CONPT), if any.
2.7 Cardiovascular Disease Related Group

2.7.1 Obesity Assessment

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Nutrition Program, Jean Charles-Azure

**National Reporting**
NATIONAL (included in National GPRA Report; *not* reported to OMB and Congress)

**Denominator**
Active Clinical patients ages 2 through 74, broken down by gender and age groups:

**Numerator**
1. All patients for whom BMI can be calculated, *including refusals in the past year*.
   
   **Note:** *This numerator does not include refusals.*

   - For those with a BMI calculated, patients considered overweight but not obese using BMI and standard tables.
   - For those with a BMI calculated, patients considered obese using BMI and standard tables.
   - Total of overweight and obese.

2. Patients with documented refusal in past year.

**Definitions**

**Age**
Age is calculated at beginning of the report period

**BMI**
CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults 19 and older. Obese is defined as BMI of 30 or more for adults 19 and older. For ages 2–18, definitions are based on standard tables.
Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.

Refusals
Include REF (refused), NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and weight must be refused during the past year and are not required to be on the same visit.

Patient List
List of patients for whom BMI could not be calculated.

2.7.2 Childhood Weight Control

No changes from Version 10.0 Patch 1

Owner/Contact
Nutrition Program, Tammy Brown

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominator
Active Clinical Patients 2–5 for whom a BMI could be calculated, broken out by age groups and gender.

Numerators
1. Patients with BMI in the 85th to 94th percentile
2. Patients with a BMI at or above the 95th percentile.
3. Patients with a BMI at or above the 85th percentile.

Definitions

Age
All patients for whom a BMI could be calculated and who are between the ages of 2 and 5 at the beginning of the report period and who do not turn age 6 during the report period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be 2 at the beginning of the time period but is 3 at the time of the most current BMI found. That patient will fall into the Age 3 group.
BMI

CRS looks for the most recent BMI in the report period. CRS calculates BMI at the time the report is run, using NHANES II. A height and weight must be taken on the same day any time during the report period. The BMI values for this measure reported differently than in Obesity Assessment since this age group is children ages 2–5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

A patient whose BMI either is greater or less than the Data Check Limit range shown below will not be included in the report counts for Overweight or Obese.

<table>
<thead>
<tr>
<th>Low-High Ages</th>
<th>Sex</th>
<th>BMI (Overweight)</th>
<th>BMI (Obese)</th>
<th>Data Check Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BMI &gt;</td>
<td>BMI &lt;</td>
<td></td>
</tr>
<tr>
<td>2-2</td>
<td>Male</td>
<td>17.7</td>
<td>18.7</td>
<td>36.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17.5</td>
<td>18.6</td>
<td>37.0</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>17.0</td>
<td>18.1</td>
<td>35.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17.1</td>
<td>18.0</td>
<td>35.4</td>
</tr>
<tr>
<td>3-3</td>
<td>Male</td>
<td>16.8</td>
<td>17.8</td>
<td>36.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16.7</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>16.9</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16.9</td>
<td>18.5</td>
<td>39.2</td>
</tr>
<tr>
<td>4-4</td>
<td>Male</td>
<td>16.9</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16.9</td>
<td>18.5</td>
<td>39.2</td>
</tr>
<tr>
<td>5-5</td>
<td>Male</td>
<td>16.9</td>
<td>18.1</td>
<td>36.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16.9</td>
<td>18.5</td>
<td>39.2</td>
</tr>
</tbody>
</table>

GPRA 2011 Description

During FY 2011, achieve the tentative long-term target rate of 24% for the proportion of children with a BMI of 95% or higher.

Patient List

List of patients ages 2–5, with current BMI.

2.7.3 Nutrition and Exercise Education for At Risk Patients

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact

Patient Education Program/Mary Wachacha and Chris Lamer, PharmD
Nutrition Program/Jean Charles-Azure

National Reporting

Not reported nationally

Denominators

1. Active Clinical patients ages 6 and older considered overweight (including obese).
   Broken down by gender.
• Active Clinical patients ages 6 and older considered obese. Broken down by age and gender.

2. Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the report period, and at least 2 visits during the report period, and 2 DM-related visits ever.

Numerators
1. Patients provided with medical nutrition therapy during the report period.
2. Patients provided with nutrition education during the report period.
3. Patients provided with exercise education during the report period.
4. Patients provided with other related exercise and nutrition (lifestyle) education.

Definitions

Age
Age of the patient is calculated at beginning of report period.

Diabetes
First DM POV 250.00–250.93 recorded in the V POV file prior to the report period.

Overweight Categories
Defined as including both obese and overweight categories calculated by BMI.

• **Overweight**
  – Ages 19 and older, BMI equal to or greater than (=>) 25.

• **Obese**
  – Ages 19 and older, BMI equal to or greater than (=>) 30.

• For ages 18 and under, definition based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

Medical Nutrition Therapy
• CPT 97802-97804, G0270, G0271
• Primary or secondary provider codes 07, 29
• Clinic codes 67 or 36

Nutrition Education
Patient Education codes ending “-N” or ”-MNT” (or old code “-DT” (Diet)) or containing V65.3, 97802-97804, G0270, or G0271; POV V65.3.
Exercise Education
POV V65.41 exercise counseling or patient education codes ending "-EX" (Exercise) or containing V65.41.

Related Exercise and Nutrition Education
Patient education codes ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00 or 278.01.

Patient List
List of at risk patients, with education if any.

2.7.4 Physical Activity Assessment

No changes from Version 10.0 Patch 1

Owner/Contact
Patient Education Program/Mary Wachacha and Chris Lamer, PharmD Nutrition Program/Jean Charles-Azure

Denominators
1. Active Clinical patients ages 5 and older. Broken down by gender and age group.
2. Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age group.

Numerators
1. Patients assessed for physical activity during the Report Period.
   • Patients from Numerator 1 who have received exercise education following their physical activity assessment.

Definitions

Age
Age is calculated at the beginning of the report period.

Physical Activity Assessment
• Any health factor for category Activity Level documented during the Report Period.

Exercise Education
• POV V65.41 exercise counseling; patient education codes ending "-EX" (Exercise) or containing V65.41
Patient List
List of patients with physical activity assessment and any exercise education.

2.7.5 Comprehensive Health Screening

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Lisa Dolan and Jana Towne

Denominators
1. Active Clinical patients ages 2 and older who are eligible for alcohol, depression, IPV/DV, tobacco, BMI, BP and physical activity screening/assessment.
2. Active Clinical patients ages 2 and older who are eligible for alcohol, depression, IPV/DV, tobacco, BMI, and BP screening/assessment.
3. Active Clinical patients ages 12 to 75.
4. Active Clinical patients ages 18 and older.
5. Female Active Clinical patients ages 15–40.
6. Active Clinical patients ages 5 and older.
7. Active Clinical patients ages 2 through 74.
8. All Active Clinical patients ages 20 and over.
9. Active Clinical patients ages 5 and older.

Numerators
1. All Comprehensive Health Screening: Patients with Comprehensive Health Screening for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use, BP, and physical activity assessed.
   
   Note: This does not include refusals.

2. Comprehensive Health Screening: Patients with Comprehensive Health Screening minus physical activity assessment for which they are eligible, defined as having alcohol, depression, and IPV/DV screening, BMI calculated, and tobacco use and BP assessed.
   
   Note: This does not include physical activity assessment and does not include refusals.

3. Alcohol Screening: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period.
   
   Note: This numerator does not include refusals or alcohol-related patient education.
4. Depression Screening: Patients screened for depression or diagnosed with a mood disorder at any time during the Report Period.

**Note:** This numerator does *not* include refusals.

5. IPV/DV Screening: Patients screened for IPV/DV at any time during the Report Period.

**Note:** This numerator does *not* include refusals.

6. Tobacco Use Assessed: Patients who have been screened for tobacco use during the Report period.

7. BMI Available: Patients for whom a BMI could be calculated.

**Note:** This numerator does *not* include refusals.

8. BP Assessed: Patients with BP value documented at least twice in prior two years.


**Definitions**

**Age**

Age is calculated at the beginning of the report period.

**Alcohol Screening**

Any of the following during the report period:

- PCC Exam Code 35
- Any CAGE Alcohol Health Factor
- Screening Diagnosis V11.3; V79.1, or BHS Problem Code 29.1
- CPT 99408, 99409, G0396, G0397, H0049, H0050
- V Measurement in PCC or BH of AUDT, AUDC, or CRFT

**Alcohol-Related Diagnosis or Procedure**

Any of the following during the report period:

- Alcohol-Related Diagnosis
  - POV, Current PCC or BHS Problem List 303.*, 305.0*; 291.*; 357.5*
  - BHS POV 10, 27, 29
- Alcohol-Related Procedure
  - Procedure 94.46, 94.53, 94.61–94.63, 94.67–94.69

**Depression Screening**

Any of the following:
• Exam Code 36
• POV V79.0
• BHS Problem Code 14.1 (screening for depression)
• V Measurement in PCC or BH of PHQ2 or PHQ9

**Mood Disorders**
At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.

• These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 or BHS POV 14 or 15

**IPV/DV Screening**
Defined as at least one of the following:

• **IPV/DV Screening**
  – PCC Exam Code 34
  – BHS IPV/DV exam

• **IPV/DV Related Diagnosis**
  – POV, Current PCC or BHS Problem List 995.80–83, 995.85, V15.41, V15.42, V15.49
  – BHS POV 43.*, 44.*

• **IPV/DV Patient Education**
  – Patient Education codes containing “DV-” or “-DV”, 995.80–83, 995.85, V15.41, V15.42, or V15.49

• **IPV/DV Counseling**
  – POV V61.11

**Tobacco Screening**
• Any Health Factor for category Tobacco, *TOBACCO (SMOKING)*, *TOBACCO (SMOKELESS–CHEWING/DIP)*, or *TOBACCO (EXPOSURE)*
• POV or Current PCC Problem List 305.1, 305.1* (old codes), 649.00–649.04, or V15.82 (tobacco-related diagnosis)
• Dental Code 1320
• Patient Education codes containing “TO-”, “-TO”, “-SHS,” 305.1, 305.1* (old codes), 649.00–649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402, or G8453

• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), or 1036F (Current Tobacco Non-User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed), G8455 (Current Tobacco Smoker), G8456 (Current Smokeless Tobacco User), G8457 (Tobacco Non-User), G8402 (Tobacco (Smoke) Use Cessation Intervention, Counseling), or G8453 (Tobacco Use Cessation Intervention, Counseling)

BMI
CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years, not required to be recorded on same day.

BP Documented
CRS uses mean of last three BPs documented on non-ER visits in the past two years. If three BPs are not available, uses mean of last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

If CRS is not able to calculate a mean BP, it will search for CPT 3074F–3080F documented on a non-ER visit during the Report Period.

Physical Activity Assessment
• Any health factor for category Activity Level documented during the Report Period.

Patient List
List of patients with assessments received, if any.

2.7.6 Cardiovascular Disease and Cholesterol Screening

Changes from Version 10.0 Patch 1, as noted.
Owner/Contact

Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD

National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators

1. Active Clinical patients age 23 and older; broken out by gender.
2. Active IHD patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever. Broken down by gender.

Numerators

1. Patients with documented blood total cholesterol screening any time in the past 5 years.
   - Patients with high total cholesterol levels, defined as equal to or greater than (=>) 240.
2. Patients with LDL completed in the past 5 years, regardless of result.
   - Patients with LDL <= 100
   - Patients with LDL 101–130
   - Patients with LDL 131–160
   - Patients with LDL >160

Definitions

Age
Age is calculated at the beginning of the report period.

IHD
- POV 410.0–412.*, 414.0–414.9, 428.*, or 429.2

Total Cholesterol Panel
Searches for most recent cholesterol test with a result during the report period. If more than one cholesterol test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If a cholesterol test with a result is not found, CRS searches for the most recent cholesterol test without a result.
- Total Cholesterol definition:
  - CPT 82465
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT CHOLESTEROL TAX
LDL
Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result.

- LDL Definition
  - CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX
  - For numerator LDL =<100, CPT 3048F will count as meeting the measure

Patient List
List of patients with cholesterol or LDL value if any.

2.7.7 Cardiovascular Disease and Blood Pressure Control

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Dr. Eric Brody/Mary Wachaeka Dr. Dena Wilson and Chris Lamer, PharmD

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators
1. All Active Clinical patients ages 20 and over, broken down by gender.
2. Active IHD patients, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least 2 visits during the report period, and 2 IHD-related visits ever. Broken down by gender.

Numerators
1. Patients with BP value documented at least twice in prior two years.
   - Patients with normal BP, defined as < 120/80, i.e., the mean systolic value is less than (<) 120 and the mean diastolic value is less than (<) 80.
   - Patients with Prehypertension I BP, defined as => 120/80 and < 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 and the mean diastolic value is equal to 80.
• Patients with Prehypertension II BP, defined as => 130/80 and <140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 and the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.

• Patients with Stage 1 Hypertension BP, defined as => 140/90 and <160/100, i.e., the mean systolic value is equal to or greater than (=>) 140 and less than (<) 160 and the mean diastolic value is equal to or greater than (=>) 90 and less than (<) 100.

• Patients with Stage 2 Hypertension BP, defined as => 160/100, i.e., the mean systolic value is equal to or greater than (=>) 160 and the mean diastolic value is equal to or greater than (=>) 100.

Definitions

Age
Age of the patient is calculated at beginning of the report period

IHD
• POV 410.0–412.*, 414.0–414.9, 428.*, or 429.2

BP Values (all numerators)
CRS uses mean of last three BPs documented on non-ER visits in the past two years. If three BPs are not available, uses mean of the last two non-ER BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 3074F–3080F documented on a non-ER visit during the report period.

Patient List
List of Patients => 20 or who have IHD with BP value, if any.

2.7.8 Controlling High Blood Pressure

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD

Performance Measure List and Definitions
December 2010
National Reporting
   Not reported nationally

Denominator
   Active Clinical patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD, broken down by age (18–85, 18–45, 46–85) and gender.

Numerators
   1. Patients with BP values documented during the report period.
      - Patients with normal BP, defined as < 120/80, i.e., the mean systolic value is less than (<) 120 and the mean diastolic value is less than (<) 80.
      - Patients with Prehypertension I BP, defined as => 120/80 and < 130/80, i.e., the mean systolic value is equal to or greater than (=>) 120 and less than (<) 130 and the mean diastolic value is equal to 80.
      - Patients with Prehypertension II BP, defined as => 130/80 and <140/90, i.e., the mean systolic value is equal to or greater than (=>) 130 and less than (<) 140 and the mean diastolic value is equal to or greater than (=>) 80 and less than (<) 90.
      - Patients with Stage 1 Hypertension BP, defined as => 140/90 and <160/100, i.e., the mean systolic value is equal to or greater than (=>) 140 and less than (<) 160 and the mean diastolic value is equal to or greater than (=>) 90 and less than (<) 100.
      - Patients with Stage 2 Hypertension BP, defined as => 160/100, i.e., the mean systolic value is equal to or greater than (=>) 160 and the mean diastolic value is equal to or greater than (=>) 100.

Definitions
   Age
   Age of the patient is calculated at beginning of the report period

   ESRD
   Any of the following ever:
   - CPT 36145, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831–36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90918–90925 (old codes), 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90951-90970, 90989, 90993, 90997, 90999, 99512, G0257, G0308–G0327 (old codes), G0392 (old code), G0393 (old code), or S9339
   - POV 585.5, 585.6 or V45.1 (old code), V45.11 V45.12
   - Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93–39.95, 54.98, or 55.6*
Hypertension
Diagnosis (POV or problem list) 401.* prior to the report period, and at least one hypertension POV during the report period.

BP Values (All Numerators)
Uses mean of last three BPs documented on non-ER visits during the report period. If three BPs are not available, uses mean of last two, non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 3074F–3080F, 3074F–3076F, 3078F–3079F documented on a non-ER visit during the report period.

Patient List
List of patients with hypertension and BP value, if any.

2.7.9 Comprehensive CVD-Related Assessment

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. **GPRA**: Active IHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least two visits during the report period, and two IHD-related visits ever.
   - Active IHD patients 22 and older who are not Active Diabetic.
   - Active IHD patients 22 and older who are Active Diabetic.

Numerators
1. Patients with BP value documented at least twice in prior two years.
2. Patients with LDL completed in past five years, regardless of result.
3. Patients who have been screened for tobacco use during the report period.
4. BMI Available: Patients for whom a BMI could be calculated.

**Note:** This does not include depression screening.

5. Lifestyle Counseling: Patients who have received any lifestyle adaptation counseling, including medical nutrition therapy, or nutrition, exercise or other lifestyle education during the current report period.

6. **GPRA:** Patients with comprehensive CVD assessment, defined as having BP, LDL, and tobacco use assessed, BMI calculated and lifestyle counseling.

**Note:** This does not include depression screening and does not include refusals of BMI.

7. Refusal of BMI: Patients who refused a height or weight measurement and for whom a BMI could not be calculated.

8. Patients screened for depression or diagnosed with a mood disorder at any time during the report period, **including documented refusals in past year.**

**Note:** This numerator does not include refusals.

---

**Definitions**

**Age**

Age of the patient is calculated at beginning of the report period.

**Diabetes**

Diagnosed with diabetes (first POV in V POV with 250.00–250.93) prior to the current report period, *and* at least two visits during the current report period, *and* two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.

**IHD**

- POV 410.0-412.*, 414.0-414.9, 428.* or 429.2

**BP**

Having a minimum of two BPs documented on non-ER visits in past two years. If CRS does not find two BPs, it will search for CPT 3074F–3080F (added codes 3074F–3076F, 3078F–3079F) documented on non-ER visit during the past two years.

**LDL**

Finds the most recent test done in the last 5 years, regardless of the results of the measurement.

- LDL Definition
CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F

- LOINC taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

**Tobacco Screening**

At least one of the following:

- Any health factor for category Tobacco, *TOBACCO (SMOKING)*, *TOBACCO (SMOKELESS–CHEWING/DIP)*, or *TOBACCO (EXPOSURE)* documented during current report period
- Tobacco-related diagnoses (POV or current Active Problem List) 305.1, 305.1* (old codes), 649.00–649.04, or V15.82
- Dental code 1320
- Any patient education code containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00–649.04, V15.82, **D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402 or G8453**
- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402 or G8453

**BMI**

CRS calculates BMI at the time the report is run, using NHANES II. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years not required to be recorded on same day.

**Medical Nutrition Therapy**

- Any of the following:
  - CPT 97802–97804, G0270, G0271
  - Primary or secondary provider codes 07, 29, 97, 99
  - Clinic Codes 67 (dietary) or 36 (WIC)

**Nutrition education:**

- POV V65.3 dietary surveillance and counseling
- Patient education codes ending “-N” (Nutrition) or “-MNT” or containing V65.3 (or old code “-DT” (Diet))

**Exercise education:**

- POV V65.41 exercise counseling
- Patient education codes ending “-EX” (Exercise) or containing V65.41
Related exercise and nutrition education:
- Patient education codes ending “-LA” (lifestyle adaptation) or containing “OBS-” (obesity) or 278.00 or 278.01.

BMI Refusals
Refusals of a height and weight measurement include REF, NMI, and UAS and must be documented during the past year. For ages 19 and older, the height and the weight must be refused during the past year and are not required to be on the same visit.

Depression Screening/Mood Disorder DX
Any of the following during the report period:
- Depression Screening:
  - Exam Code 36
  - POV V79.0
  - BHS Problem Code 14.1 (screening for depression)
  - V Measurement in PCC or BH of PHQ2 or PHQ9

— Refusal, defined as any PCC refusal in past year with Exam Code 36
- Mood Disorder DX
  - At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS.
    - These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 or BHS POV 14 or 15

GPRA 2011 Description
During FY 2011, achieve the tentative target rate of 35.8% for the proportion of at-risk patients who have a comprehensive assessment.

Patient List
List of patients with assessments received, if any.

2.7.10  Appropriate Medication Therapy after a Heart Attack

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD
National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominator

Active Clinical patients 35 and older discharged for an AMI during the first 51 weeks of the report period and were not readmitted for any diagnosis within seven days of discharge. Broken down by gender.

Numerators

1. Patients with active prescription for, refusal of, or who have a contraindication/previous adverse reaction to beta-blockers.
   - Patients with active prescription for beta-blockers.
   - Patients with documented refusal of beta-blockers.
   - Patients with contraindication/previous adverse reaction to beta-blocker therapy.

2. Patients with active prescription for, refusal of, or who have a contraindication/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.
   - Patients with active prescription for ASA (aspirin) or other anti-platelet agent.
   - Patients with documented refusal of ASA (aspirin) or other anti-platelet agent.
   - Patients with contraindication/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

3. Patients with active prescription for, refusal of, or who have a contraindication/previous adverse reaction to ACEIs/ARBs.
   - Patients with active prescription for ACEIs/ARBs
   - Patients with documented refusal of ACEIs/ARBs
   - Patients with contraindication/previous adverse reaction to ACEIs/ARBs

4. Patients with active prescription for, refusal of, or who have a contraindication/previous adverse reaction to statins.
   - Patients with active prescription for statins
   - Patients with documented refusal of statins
   - Patients with contraindication/previous adverse reaction to statins

5. Patients with active prescriptions for all post-AMI medications (i.e. beta-blocker, ASA/anti-platelet, ACEI/ARB, AND statin), with refusal, and/or who have a contraindication/previous adverse reaction.
Definitions

**Age**

Age is calculated at the beginning of the report period.

**AMI**

- POV 410.*1 (i.e., first eligible episode of an AMI) with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the report period, CRS will include only the first discharge.

**Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- Patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death.”
- Patients readmitted for any diagnosis within seven days of discharge.
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).

**To be included in the numerators,**

A patient must meet one of the three conditions below:

- An active prescription (not discontinued as of \([\text{discharge date} + 7 \text{ days}] \) and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within seven days after discharge. "Active" prescription defined as: Days Prescribed > \(((\text{Discharge Date} + 7 \text{ days})–\text{Order Date}); or
- A refusal of the medication at least once during hospital stay through 7 days after discharge date; or
- Have a contraindication/previous adverse reaction to the indicated medication.

Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/allergy will be counted in sub-numerators B-C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A-C may not add up to the to the numerator total.
**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

**Numerator Logic**

In the logic below, “ever” is defined as anytime through the end of the report period.

**Beta-Blocker Numerator Logic**

- **Beta-blocker medication codes**
  - Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  - Medications are:
    - Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol

- **Refusal of beta-blocker**
  - REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during hospital stay through 7 days after discharge date.

- **Contraindications to beta-blockers**
  Defined as any of the following occurring ever unless otherwise noted:
  - Asthma–2 diagnoses (POV) of 493* on different visit dates
  - Hypotension–1 diagnosis of 458*
  - Heart block >1 degree–1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7
  - Sinus bradycardia–1 diagnosis of 427.81
  - COPD–2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
  - NMI refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date
- CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) at least once during hospital stay through 7 days after discharge date

**Adverse drug reaction/documentated beta blocker allergy**

Defined as any of the following occurring ever:
- POV 995.0–995.3 AND E942.0
- Beta block* entry in ART (Patient Allergies File)
- Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ASA (aspirin)/Other Anti-Platelet Numerator Logic**

- **ASA medication codes**
  - Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS
- **Other antiplatelet medication codes**
  - Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy
- **Refusal of ASA/other antiplatelet**:
  - REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during hospital stay through 7 days after discharge date.
- **Contraindications to ASA/other antiplatelet**
  Defined as any of the following occurring ever unless otherwise noted:
  - Patients with active prescription for Warfarin/Coumadin at time of arrival or prescribed at discharge, using site-populated BGP CMS WARFARIN MEDS taxonomy
  - Hemorrhage diagnosis (POV 459.0)
  - NMI refusal for any aspirin at least once during hospital stay through 7 days after discharge date
  - CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) at least once during hospital stay through 7 days after discharge date
- **Adverse drug reaction/documentated ASA/other antiplatelet allergy**
  Defined as any of the following occurring ever:
  - POV 995.0–995.3 and E935.3
  - Aspirin entry in ART (Patient Allergies File)
  - ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0-995.3 or V14.8
ACEI/ARB Numerator Logic

- **ACEI medication codes**
  Defined with medication taxonomy BGP HEDIS ACEI MEDS.
  - **ACEI medications are**: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).


- **Refusal of ACEI**:
  - REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during hospital stay through 7 days after discharge date.

- **Contraindications to ACEI** defined as any of the following:
  - **Pregnancy**: defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0-V23.9, V72.42, 640.*-649.*, 651.*-676.*). *Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.* If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition**:
      - POV 630, 631, 632, 633*, 634*
      - CPT 59812, 59820, 59821, 59830
    - **Abortion definition**:
      - POV 635*, 636* 637*
      - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      - Procedure 69.01, 69.51, 74.91, 96.49
  - **Diagnosis ever for moderate or severe aortic stenosis**
    - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
  - **NMI refusal** for any ACEI at least once during hospital stay through 7 days after discharge date.
• **Adverse drug reaction/documentated ACEI allergy**

  Defined as any of the following occurring ever:
  
  – POV 995.0-995.3 *and* E942.6
  – Ace inhibitor or ACEI entry in ART (Patient Allergies File)
  – Ace i* or ACEI contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

• **ARB (Angiotensin Receptor Blocker) medication codes**

  Defined with medication taxonomy BGP HEDIS ARB MEDS
  
  – **ARB medications are:** Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

• **Antihypertensive Combinations**


• **Refusal of ARB**

  – REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during hospital stay through 7 days after discharge date.

• **Contraindications to ARB** defined as any of the following:

  – **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.* –649.*, 651.* – 676.*). *Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.* If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.

    – **Miscarriage definition:**
      – POV 630, 631, 632, 633*, 634*
      – CPT 59812, 59820, 59821, 59830

    – **Abortion definition:**
      – POV 635*, 636* 637*
      – CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      – Procedure 69.01, 69.51, 74.91, 96.49

- **Diagnosis ever for moderate or severe aortic stenosis**
  - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22

- **NMI refusal** for any ARB at least once during hospital stay through 7 days after discharge date.

- **Adverse drug reaction/documenting ARB allergy**
  Defined as any of the following occurring ever:
  - POV 995.0–995.3 and E942.6
  - Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
  - Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**Statins Numerator Logic:**

- **Statin medication codes**
  - Defined with medication taxonomy BGP HEDIS STATIN MEDS.
  - **Statin medications are**: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor).

- **Statin Combination Products**
  - Advicor, Caduet, PraviGard Pac, Vytorin.

- **Refusal of Statin**
  - REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during hospital stay through 7 days after discharge date.

- **Contraindications to Statins**: defined as any of the following:
  - **Pregnancy**: defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0-V23.9, V72.42, 640.*-649.*, 651.*-676.*). *Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.* If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition**:
      - POV 630, 631, 632, 633*, 634*
      - CPT 59812, 59820, 59821, 59830
Abortion definition:
- POV 635*, 636* 637*
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
- Procedure 69.01, 69.51, 74.91, 96.49


Acute Alcoholic Hepatitis: defined as POV 571.1 during the Report Period

NMI refusal for any statin at least once during hospital stay through 7 days after discharge date.

- Adverse drug reaction/documenting statin allergy
  Defined as any of the following:
  - ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period
  - Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period
  - Myopathy/Myalgia, defined as any of the following during the Report Period:
    - POV 359.0–359.9, 729.1, 710.5, or 074.1
  - Any of the following occurring ever:
    - POV 995.0–995.3 AND E942.9
    - Statin or Statins entry in ART (Patient Allergies File)
    - Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

All Medications Numerator Logic
To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for all of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, AND statin).

Test Definitions
- ALT
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy
- AST
  - Site-populated taxonomy DM AUDIT AST TAX
LOINC taxonomy

**Creatine Kinase**
- Site-populated taxonomy BGP CREATINE KINASE TAX
- LOINC taxonomy

**Patient List**
List of patients with AMI, with appropriate medication therapy, if any.

### 2.7.11 Persistence of Appropriate Medication Therapy after a Heart Attack

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Dr. Eric Brody/Mary Waichacha Dr. Dena Wilson and Chris Lamer, PharmD

**National Reporting**
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

**Denominator**
Active Clinical patients 35 and older diagnosed with an AMI 6 months prior to the report period through the first 6 months of the report period. Broken down by gender.

**Numerators**

1. Patients with a 135-day course of treatment with beta-blockers, who refused beta-blockers in the 180 days after AMI, or who have a contraindication/previous adverse reaction to beta-blocker therapy.
   - Patients with 135-day treatment with beta-blockers.
   - Patients with documented refusal of beta-blockers.
   - Patients with contraindications/previous adverse reaction to beta-blockers.

2. Patients with a 135-day course of treatment with ASA (aspirin) or other antiplatelet agent, who refused ASA/antiplatelet in the 180 days after AMI, or who have a contraindication/previous adverse reaction to ASA/antiplatelet therapy.
   - Patients with 135-day treatment with ASA (aspirin) or other anti-platelet agent.
   - Patients with documented refusal of ASA (aspirin) or other antiplatelet agent.
   - Patients with contraindications/previous adverse reaction to ASA (aspirin) or other anti-platelet agent.
3. Patients with a 135-day course of treatment with ACEIs/ARBs, who refused ACEIs/ARBs in the 180 days after AMI, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.
   • Patients with 135-day treatment with ACEIs/ARBs.
   • Patients with documented refusal of ACEIs/ARBs.
   • Patients with contraindications/previous adverse reaction to ACEIs/ARBs.

4. Patients with a 135-day course of treatment with statins, who refused statins in the 180 days after AMI, or who have a contraindication/previous adverse reaction to statin therapy.
   • Patients with 135-day treatment with statins.
   • Patients with documented refusal of statins.
   • Patients with contraindications/previous adverse reaction to statins.

5. Patients with a 135-day course of treatment for all post-AMI medications, (i.e. beta-blocker, ASA/anti-platelet, ACEI/ARB, AND statin) following first discharge date or visit date, including previous active prescriptions; with refusal, and/or who have a contraindication/previous adverse reaction.

Definitions

Age
Age is calculated at the beginning of the report period.

AMI
POV or Problem List 410.0*–410.9* or 412. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between six months prior to beginning of report period through first six months of the report period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.

Denominator Exclusions
Patients meeting any of the following conditions will be excluded from the denominator.

• If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains “Death.”

• Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).

• Patients with a Provider Narrative beginning with “Consider,” “Doubtful,” “Maybe,” “Possible,” “Perhaps,” “Rule Out,” “R/O,” “Probable,” “Resolved,” “Suspect,”; “Suspicious,” or “Status Post.”
To be included in the numerators, a patient must meet one of the three conditions below:

- A total days’ supply $\geq 135$ days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Medications must not have a comment of RETURNED TO STOCK. Prior active prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent prescription (see codes below) prior to admission/visit date with the number of days supply equal to or greater than the discharge/visit date minus the prescription date.

- A refusal of the medication at least once at time of diagnosis through the 180 days after AMI.

- Have a contraindication/previous adverse reaction to the indicated medication. Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/allergy will be counted in sub-numerators B-C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A-C may not add up to the numerator total.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

**Example of patient included in the beta-blocker numerator who has prior active prescription:**

- Admission Date: 2/1/2011, Discharge Date: 2/15/2011
- Must have 135 days prescribed by 8/13/2011 (Discharge Date+180)
- Prior Beta-Blocker Rx Date: 1/15/2011
- # Days Prescribed: 60 (treats patient through 3/15/2011)
- Discharge Date minus Rx Date: 2/15/2011–1/15/2011 = 31, 60 is $\geq 31$, prescription is considered Prior Active Rx
- 3/15/2011 is between 2/15 and 8/13/2011, thus remainder of Prior Active Rx can be counted toward 180-day treatment period
- # Remaining Days Prescribed from Prior Active Rx: (60-(Discharge Date-Prior Rx Date) = 60-(2/15/2011–1/15/2011) = 6031 = 29
- Rx #2: 4/1/2011, # Days Prescribed: 90
Numerical Logic

In the logic below, “ever” is defined as anytime through the end of the report period.

Beta-Blocker Numerator Logic

- **Beta-blocker medication codes:**
  - Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  - Medications are:
    - Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol

- **Refusal of beta-blocker**
  - REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Contraindications to beta-blockers**
  - Defined as any of the following occurring ever unless otherwise noted:
    - Asthma–2 diagnoses (POV) of 493* on different visit dates
    - Hypotension–1 diagnosis of 458*
    - Heart block >1 degree–1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7
    - Sinus bradycardia–1 diagnosis of 427.81
    - COPD–2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
    - NMI refusal for any beta-blocker at least once during the period admission/visit date through the 180 days after discharge/visit date
    - CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) at least once during the period admission/visit date through the 180 days after discharge/visit date
• **Adverse drug reactiondocumento beta blocker allergy**
  Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:
  – POV 995.0-995.3 and E942.0
  – Beta block* entry in ART (Patient Allergies File)
  – Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**ASA (aspirin) Numerator Logic**

• **ASA medication codes**
  – Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

• **Other antiplatelet medication codes**
  – Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy

• **Refusal of ASA/other antiplatelet**
  – REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during the period admission/visit date through the 180 days after discharge/visit date.

• **Contraindications to ASA/other antiplatelet**
  Defined as any of the following occurring ever unless otherwise noted:
  – Patients with prescription for Warfarin/Coumadin using site-populated BGP CMS WARFARIN MEDS taxonomy during the period admission/visit date through the 180 days after discharge/visit date
  – Hemorrhage diagnosis (POV 459.0)
  – NMI refusal for any aspirin at least once during the period admission/visit date through the 180 days after discharge/visit date
  – CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) at least once during the period admission/visit date through the 180 days after discharge/visit date

• **Adverse drug reaction documented ASA/other antiplatelet allergy**
  Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:
  – POV 995.0–995.3 AND E935.3
  – Aspirin entry in ART (Patient Allergies File)
  – ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8
ACEI/ARB Numerator Logic

- **ACEI medication codes**
  
  Defined with medication taxonomy BGP HEDIS ACEI MEDS.
  
  - ACEI medications are: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).

- **Antihypertensive Combinations**:

- **Refusal of ACEI**
  
  - REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

- **Contraindications to ACEI**
  
  - Pregnancy: defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.* –649.*, 651.* –676.*). 
    
    Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    
    - Miscarriage definition:
        
        - POV 630, 631, 632, 633*, 634*
        - CPT 59812, 59820, 59821, 59830
    
    - Abortion definition:
        
        - POV 635*, 636* 637*
        - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267,
        - Procedure 69.01, 69.51, 74.91, 96.49
        
        - Breastfeeding: defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date
        
        - Diagnosis ever for moderate or severe aortic stenosis
            
            - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
• **NMI refusal** for any ACEI at least once during the period admission/visit date through the 180 days after discharge/visit date.

**Adverse drug reaction/documentated ACEI allergy**

Defined as any of the following occurring ever:

- POV 995.0–995.3 and E942.6
- Ace inhibitor or ACEI entry in ART (Patient Allergies File)
- Ace i* or ACEI contained within Problem List or in Provider Narrative field for any POV 995.0-995.3 or V14.8.

**ARB (Angiotensin Receptor Blocker) medication codes**

Defined with medication taxonomy BGP HEDIS ARB MEDS

- **ARB medications are:** Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan)

**Antihypertensive Combinations**


**Refusal of ARB**

- REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the period admission/visit date through the 180 days after discharge/visit date.

**Contraindications to ARB** defined as any of the following:

- **Pregnancy:** defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640. *–649.*, 651.*–676.*). *Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.* If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  - **Miscarriage definition:**
    - POV 630, 631, 632, 633*, 634*
    - CPT 59812, 59820, 59821, 59830
  - **Abortion definition:**
    - POV 635*, 636* 637* 636*
    - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
– Procedure 69.01, 69.51, 74.91, 96.49

– Breastfeeding: defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, or BF-N during the period admission/visit date through the 180 days after discharge/visit date

– Diagnosis ever for moderate or severe aortic stenosis
  – POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22

– NMI refusal for any ARB at least once during the period admission/visit date through the 180 days after discharge/visit date.

• Adverse drug reaction/document ARB allergy
  Defined as any of the following occurring anytime up to the 180 days after discharge/visit date:
  – POV 995.0-995.3 and E942.6
  – Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
  – Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

Statins Numerator Logic

• Statin medication codes
  – Defined with medication taxonomy BGP HEDIS STATIN MEDS
  – Statin medications are: Atorvostatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor)

• Statin Combination Products
  – Advicor, Caduet, PraviGard Pac, Vytorin

• Refusal of Statin
  – REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during admission/visit date through the 180 days after discharge/visit date.

• Contraindications to Statins: Defined as any of the following:
  – Pregnancy: Defined as at least two visits during the period admission/visit date through the 180 days after discharge/visit date with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*).

Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the period, CRS will use the first two visits in the period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
Miscarriage definition:
- POV 630, 631, 632, 633*, 634*
- CPT 59812, 59820, 59821, 59830

Abortion definition:
- POV 635*, 636* 637*
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260-S2267
- Procedure 69.01, 69.51, 74.91, 96.49

Breastfeeding: Defined as POV V24.1 or breastfeeding patient education codes BF-BC, BF-BP, BF-CS, BF-EQ, BF-FU, BF-HC, BF-ON, BF-M, BF-MK, BF-N during the period admission/visit date through the 180 days after discharge/visit date

Acute Alcoholic Hepatitis: Defined as POV 571.1 during the period admission/visit date through the 180 days after discharge/visit date

NMI (not medically indicated) refusal for any statin at least once during the period admission/visit date through the 180 days after discharge/visit date.

• Adverse drug reaction/documentated statin allergy

- ALT and/or AST > 3x the Upper Limit of Normal (ULN) (i.e., Reference High) on 2 or more consecutive visits during the period admission/visit date through the 180 days after discharge/visit date
- Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the period admission/visit date through the 180 days after discharge/visit date
- Myopathy/Myalgia, defined as any of the following during the period admission/visit date through the 180 days after discharge/visit date:
  - POV 359.0–359.9, 729.1, 710.5, or 074.1
  - Any of the following occurring anytime up to the 180 days after discharge/visit date:
    - POV 995.0–995.3 and E942.9
    - Statin or Statins entry in ART (Patient Allergies File)
    - Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

All Medications Numerator Logic

To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for all of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, and statin).
Test Definitions

- **ALT**
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy

- **AST**
  - Site-populated taxonomy DM AUDIT AST TAX
  - LOINC taxonomy

- **Creatine Kinase**
  - Site-populated taxonomy BGP CREATINE KINASE TAX
  - LOINC taxonomy

Patient List

List of patients with AMI, with persistent medication therapy, if any.

### 2.7.12 Appropriate Medication Therapy in High Risk Patients

**Changes from Version 10.0 Patch 1, as noted.**

Owner/Contact

Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD

National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators

1. Active IHD patients ages 22 and older, defined as all Active Clinical patients diagnosed with IHD prior to the report period, and at least 2 visits during the report period, and 2 IHD-related visits ever.
   - Active IHD patients age 22 and older who are not Active Diabetic.
   - Active IHD patients age 22 and older who are Active Diabetic.

Numerators

1. Patients with a 180-day course of treatment with or refusal of beta-blockers during the report period, or who have a contraindication/previous adverse reaction to beta-blocker therapy.
   - Patients with 180-day treatment with beta-blockers.
   - Patients with documented refusal of beta-blockers.
   - Patients with contraindications/previous adverse reaction to beta-blockers.
2. Patients with a 180-day course of treatment with or refusal of ASA (aspirin) or other antiplatelet agent during the report period, or who have a contraindication/previous adverse reaction to ASA/antiplatelet therapy.
   - Patients with 180-day treatment with ASA (aspirin) or other anti-platelet agent.
   - Patients with documented refusal of ASA (aspirin) or other antiplatelet agent.
   - Patients with contraindications/previous adverse reaction to ASA (aspirin) or other antiplatelet agent.

3. Patients with a 180-day course of treatment with or refusal of ACEIs/ARBs during the report period, or who have a contraindication/previous adverse reaction to ACEI/ARB therapy.
   - Patients with 180-day treatment with ACEIs/ARBs.
   - Patients with documented refusal of ACEIs/ARBs.
   - Patients with contraindications/previous adverse reaction to ACEIs/ARBs.

4. Patients with a 180-day course of treatment with or refusal of statins during the report period, or who have a contraindication/previous adverse reaction to statin therapy.
   - Patients with 180-day treatment with statins.
   - Patients with documented refusal of statins.
   - Patients with contraindications/previous adverse reaction to statins.

5. Patients with a 180-day course of treatment for all medications (i.e. beta-blocker, aspirin/antiplatelet, ACEI/ARB, and statin) during the report period, with refusal, and/or who have a contraindication/previous adverse reaction.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period

**IHD**

- POV 410.0–412.*, 414.0–414.9, 428.* or 429.2

**Diabetes**

Diagnosed with diabetes (first POV in V POV with 250.00–250.93) prior to the current report period, and at least two visits during the current report period, and two DM-related visits ever. Patients not meeting these criteria are considered non-diabetics.
To be included in the numerators:

A patient must meet one of the three conditions below:

- Prescription(s) for the indicated medication with a total days supply of 180 days or more during the Report Period. Medications must not have a comment of RETURNED TO STOCK

- A refusal of the medication during the report period

- Have a contraindication/previous adverse reaction to the indicated medication. Refusals and contraindications/previous adverse drug reactions (ADR)/allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a refusal and/or contraindication/ADR/allergy will be counted in subnumerators B-C. Because a patient may have both a refusal and a contraindication/ADR/allergy, the subnumerator totals of A-C may not add up the to the numerator total.

For prescriptions, the days supply requirement may be met with a single prescription or from a combination of prescriptions for the indicated medication that were filled during the report period and prescriptions filled prior to the report period but which are still active (i.e., prior active prescription). Prior active prescriptions can be included if the treatment days fall within the report period. Prior active prescription defined as most recent prescription for the indicated medication (see codes below) prior to report period start date with the number of days supply equal to or greater than the report period start date minus the prescription date.

Note: If a prescription for a medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

Example of patient included in the beta-blocker numerator with prior active prescription:

- Report period: 07/01/2010–06/30/2011
- Must have 180 days supply of indicated medication 6/30/2011 (end of report period)
- Prior Beta-Blocker Rx Date: 06/01/2010
- # Days Prescribed: 60 (treats patient through 07/31/2010)
- Report Period Start Date minus Rx Date: 07/01/2010-06/01/2010 = 30; 60 (#Days Prescribed) is >= 30, prescription is considered Prior Active Rx
- 07/31/2010 is between the report period of 07/01/2010 and 06/30/2011, thus remainder of Prior Active Rx can be counted toward 180-days supply
# Remaining Days Prescribed from Prior Active Rx:
\[
\text{# Days Prescribed} - \text{(Report Period Start Date - Prior Rx Date)} = 60 - (07/01/2010 - 06/01/2010) = 60 - 30 = 30
\]

- Rx #2: 08/05/2010, # Days Prescribed: 90
- Rx #3: 11/10/2010, # Days Prescribed: 90
- Total Days Supply Prescribed between 07/01/2010 and 06/30/2011, including prior active prescription: 30+90+90=210

**Numerator Logic**

In the logic below, "ever" is defined as anytime through the end of the Report Period.

**Beta-Blocker Numerator Logic:**

- **Beta-blocker medication codes**
  - Defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS
  - Medications are:
    - Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
    - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol
    - Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, and Hydrochlorothiazide-propranolol

- **Refusal of beta-blocker**
  - REF refusal of any beta-blocker medication in site-populated medication taxonomy BGP HEDIS BETA BLOCKER MEDS at least once during the Report Period.

- **Contraindications to beta-blockers**
  Defined as any of the following occurring ever unless otherwise noted:
  - Asthma—2 diagnoses (POV) of 493* on different visit dates
  - Hypotension—1 diagnosis of 458*
  - Heart block >1 degree—1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7
  - Sinus bradycardia—1 diagnosis of 427.81
  - COPD—2 diagnoses on different visit dates of 491.2*, 496, or 506.4, or a combination of any of these codes, such as 1 visit with 491.20 and 1 with 496
  - NMI refusal for any beta-blocker at least once during the Report Period
- CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) at least once during the Report Period.

**Adverse drug reaction/documentated beta blocker allergy**

Defined as any of the following occurring ever:

- POV 995.0–995.3 AND E942.0
- Beta block* entry in ART (Patient Allergies File)
- Beta block*, bblock* or b block* contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**ASA (aspirin)/Other Antiplatelet Numerator Logic**

**ASA medication codes**

- Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS.

**Other anti-platelet medication codes**

- Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy.

**Refusal of ASA/other antiplatelet**

- REF refusal of any ASA or antiplatelet medication in site-populated medication taxonomies DM AUDIT ASPIRIN DRUGS or BGP ANTI-PLATELET DRUGS at least once during the Report Period.

**Contraindications to ASA/other antiplatelet**

Defined as any of the following occurring ever unless otherwise noted:

- Patients with a 180-day course of treatment for Warfarin/Coumadin during the Report Period, using site-populated BGP CMS WARFARIN MEDS taxonomy
- Hemorrhage diagnosis (POV 459.0)
- NMI refusal for any aspirin at least once during the Report Period
- CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) at least once during the report period

**Adverse drug reaction/documentated ASA/other anti-platelet allergy**

Defined as any of the following occurring ever:

- POV 995.0–995.3 AND E935.3
- Aspirin entry in ART (Patient Allergies File)
- ASA or aspirin contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8
ACEI/ARB Numerator Logic

- **ACEI medication codes**
  
  Defined with medication taxonomy BGP HEDIS ACEI MEDS
  
  - **ACEI medications are:** Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).


- **Refusal of ACEI**
  
  - REF refusal of any ACE Inhibitor medication in site-populated medication taxonomy BGP HEDIS ACEI MEDS at least during the Report Period.

- **Contraindications to ACEI** defined as any of the following:
  
  - **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*). **Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.** If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    
    - **Miscarriage definition:**
      
      - POV 630, 631, 632, 633*, 634*
      
      - CPT 59812, 59820, 59821, 59830
    
    - **Abortion definition:**
      
      - POV 635*, 636* 637*
      
      - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      
      - Procedure 69.01, 69.51, 74.91, 96.49
    
    
    - **Diagnosis ever for moderate or severe aortic stenosis**
      
      - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
    
    - **NMI refusal** for any ACEI at least once during the Report Period.

- **Adverse drug reaction/document ACEI allergy**
Defined as any of the following occurring anytime through the end of the report period:

- **POV 995.0–995.3 and E942.6**
- Ace inhibitor or ACEI entry in ART (Patient Allergies File)
- Ace i* or ACEI contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

- **ARB (Angiotensin Receptor Blocker) medication codes**
  Defined with medication taxonomy BGP HEDIS ARB MEDS
  - **ARB medications are:** Angiotensin II Inhibitors (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan)

- **Antihypertensive Combinations**

- **Refusal of ARB**
  - REF refusal of any ARB medication in site-populated medication taxonomy BGP HEDIS ARB MEDS at least once during the Report Period.

- **Contraindications to ARB** defined as any of the following:
  - **Pregnancy:** defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.*—649.*, 651.*—676.*). Pharmacy-only visits (Clinic Code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
    - **Miscarriage definition:**
      - POV 630, 631, 632, 633*, 634*
    - **Abortion definition:**
      - POV 635*, 636* 637*
      - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
      - Procedure 69.01, 69.51, 74.91, 96.49
- **Diagnosis ever for moderate or severe aortic stenosis**
  - POV 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22
- **NMI refusal** for any ARB at least once during the Report Period.
- **Adverse drug reaction/document ARB allergy**
  Defined as any of the following occurring anytime through the end of the Report Period:
  - POV 995.0–995.3 and E942.6
  - Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
  - Angiotensin Receptor Blocker or ARB contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8

**Statins Numerator Logic**

- **Statin medication codes**
  - Defined with medication taxonomy BGP HEDIS STATIN MEDS
  - **Statin medications are**: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor), Mevacor, Pravastatin (Pravachol), Simvastatin (Zocor), Rosuvastatin (Crestor).

- **Statin Combination Products**
  - Advicor, Caduet, PraviGard Pac, Vytorin

- **Refusal of Statin**
  - REF refusal of any statin medication in site-populated medication taxonomy BGP HEDIS STATIN MEDS at least once during the Report Period

- **Contraindications to Statins**: Defined as any of the following:
  - **Pregnancy**: defined as at least two visits during the Report Period with POV or Problem diagnosis (V22.0–V23.9, V72.42, 640.* –649.*, 651.* – 676.*). *Pharmacy-only visits (Clinic Code 39) will not count toward these two visits.* If the patient has more than two pregnancy-related visits during the Report Period, CRS will use the first two visits in the Report Period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit.
  - **Miscarriage definition**:
    - POV 630, 631, 632, 633*, 634*
    - CPT 59812, 59820, 59821, 59830
Abortion definition:
- POV 635*, 636* 637*
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
- Procedure 69.01, 69.51, 74.91, 96.49


Acute Alcoholic Hepatitis: Defined as POV 571.1 during the Report Period

NMI refusal for any statin at least once during the report period

**Adverse drug reaction/documentated statin allergy**
Defined as any of the following:
- ALT and/or AST > 3x the ULN (i.e., Reference High) on two or more consecutive visits during the Report Period
- Creatine Kinase (CK) levels > 10x ULN or CK > 10,000 IU/L during the Report Period
- Myopathy/Myalgia, defined as any of the following during the Report Period:
  - POV 359.0–359.9, 729.1, 710.5, or 074.1
- Any of the following occurring anytime through the end of the Report Period:
  - POV 995.0–995.3 and E942.9
  - Statin or Statins entry in ART (Patient Allergies File)
  - Statin or Statins contained within Problem List or in Provider Narrative field for any POV 995.0–995.3 or V14.8.

**All Medications Numerator Logic**
To be included in this numerator, a patient must have a prescription, refusal, or a contraindication for all of the four medication classes (i.e., beta-blocker, ASA/other anti-platelet, ACEI/ARB, and statin).

**Test Definitions**

- **ALT**
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy

- **AST**
  - Site-populated taxonomy DM AUDIT AST TAX
b. Creatine Kinase
   - Site-populated taxonomy BGP CREATINE KINASE TAX
   - LOINC taxonomy

Patient List
List of IHD patients 22+ with 180-day medication therapy during the report period, if any.

2.7.13 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Dr. Eric Brody
Dr. Dena Wilson

Denominators
Number of visits for User Population patients ages 18 and older who were hospitalized during the report period with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

Numerators
1. Number of visits where patients received a prescription for anticoagulant at discharge.
2. Number of visits where patients refused anticoagulant therapy.
3. Number of visits where patients did not receive anticoagulation therapy.

Definition

Age
Age is calculated as of the beginning of the report period.

Ischemic Stroke or TIA with Atrial Fibrillation:
Non-CHS inpatient visit (Type not equal to C and Service Category=H) and POV of any of the following: (433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, or 435.9) and POV 427.31 (atrial fibrillation). The patient must be admitted to the hospital during the report period with a condition described above but the discharge may occur after the report period.

Anticoagulant Therapy
Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy. For all prescriptions, medications must not have a comment of RETURNED TO STOCK.
• Active prescription for Warfarin, aspirin, or other antiplatelet as of discharge date. "Active" prescription defined as:
  – Rx Days Supply >= (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.
• Prescription for Warfarin, aspirin, or other antiplatelet on discharge date.

**Warfarin Medication**
Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

**Aspirin Medication**
Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

**Other Anti-Platelet/Anticoagulant Medication**
Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

**Refusal of Anticoagulant Therapy**
Refusal of any of the following documented on discharge date:
• Any medication in site-populated taxonomies:
  – BGP CMS WARFARIN MEDS
  – DM AUDIT ASPIRIN DRUGS
  – BGP ANTI-PLATELET DRUGS
• Any medication with VA Drug Class BL700

**No Anticoagulant Therapy**
Patients who did not have an active prescription for anticoagulant therapy at time of discharge and did not receive or refuse anticoagulant therapy at discharge.

**Patient List**
List of patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

**2.7.14 Cholesterol Management for Patients with Cardiovascular Conditions**

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
*Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson* and Chris Lamer, PharmD
National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominator

Active Clinical patients ages 18 to 75 who, during the first 10 months of the year prior to the beginning of the report period, were diagnosed with AMI, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA), or who were diagnosed with IVD during the report period and the year prior to the report period (changed timeframe for IVD). Broken down by gender.

Numerators

1. Patients with LDL completed during the report period, regardless of result.
   - A. Patients with LDL <=100, completed during the report period.
   - B. Patients with LDL 101-130, completed during the report period.
   - C. Patients with LDL >130, completed during the report period

Definitions

Age

Age of the patient is calculated at the beginning of the report period.

AMI

- POV 410.*0 or 410.*1

PTCA

- Procedure 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06–36.07, or 36.09
- CPT 33140, 92980, 92982, 92995

CABG

- Procedure 36.1*, 36.2
- CPT 33510–33514, 33516–33519, 33521–33523, 33533–33536, S2205–S2209

IVD

- POV 411.*, 413.*, 414.0*, 414.2, 414.8, 429.2, 433.*-434.*, 440.1, 440.2*, 440.4, 444.*, or 445.*
LDL

Searches for most recent LDL test with a result during the report period. If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used. If an LDL test with a result is not found, CRS searches for the most recent LDL test without a result. LDL defined as:

- CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
- LOINC taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX
- For numerator LDL =<100, CPT 3048F will count as meeting the measure

Patient List

List of patients with AMI, CABG, PTCA, or IVD with LDL value, if any.

2.7.15 Heart Failure and Evaluation of LVS Function

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact

Dr. Eric Brody/Mary Wachacha Dr. Dena Wilson and Chris Lamer, PharmD

National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominator

Active Clinical ages 18 or older discharged with heart failure during the report period.

Numerator

1. Patients whose LVS function was evaluated before arrival, during hospitalization, or is planned for after discharge.

Definitions

Age

Age of the patient is calculated as of the hospital admission date

Heart Failure

- Primary diagnosis code of 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.49, 429.1, or 997.1 and with Service Category H (hospitalization).

Note: If a patient has multiple admissions matching these criteria during the report period, the earliest admission will be used.
Denominator Exclusions
Defined as any of the following:

• Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).

• Patients with a Discharge Type of Transferred or Irregular or containing “Death.”

• Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

Comfort Measures

• V66.7 (Encounter for palliative care) documented during hospital stay

LVAD/Heart Transplant

Any of the following during hospital stay:

• Procedure 33.6, 37.41, 37.51–37.54, 37.61–37.66, 37.68

Evaluation of LVS Function

Any of the following:

• An ejection fraction ordered or documented anytime one year prior to discharge date, defined as any of the following:
  – V Measurement “CEF”
  – Procedure 88.53, 88.54
  – CPT 78414, 78468, 78472, 78473, 78480, 78481, 78494, 93303, 93304, 93307, 93308, 93312, 93314-93318, 93350, 93543, 93555
  – RCIS order for Cardiovascular Disorders referral that is ordered during the hospital stay but no later than the hospital discharge date. (RCIS referral defined as:
    – ICD Diagnostic Category Cardiovascular Disorders combined with any of the following CPT Categories: Evaluation and/or Management, Non-surgical Procedures or Diagnostic Imaging.)

• Any of the following documented anytime one year prior to discharge date:
  – Echocardiogram: Procedure 88.72, 37.28, 00.24
  – Nuclear Medicine Test: Procedure 92.2*
  – Cardiac Catheterization with a Left Ventriculogram: Procedure 37.22, 37.23, 88.53, 88.54

Patient List
List of Active Clinical heart failure patients 18+ who received evaluation of LVS function, if any.
2.8 STD-Related Group

2.8.1 HIV Screening

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Drs. Scott Giberson, Marie Russell, Jim Cheek, and John Redd

National Reporting
NATIONAL (included in National GPRA and PART Report; reported to OMB and Congress)

Denominators
1. **GPRA:** All pregnant Active Clinical patients with no documented miscarriage or abortion during the past 20 months and no recorded HIV diagnosis ever.
2. **GPRA Developmental:** User Population patients ages 13–64 with no recorded HIV diagnosis ever prior to the Report Period.

Numerators
1. **GPRA:** Patients who were screened for HIV during the past 20 months.
2. Patients with documented HIV screening refusal during the past 20 months
3. **GPRA Developmental:** Patients who were screened for HIV during the Report Period.
   
   **Note:** This numerator does not include refusals.

4. Patients with documented HIV screening refusal during the report period.
5. **GPRA Developmental:** Number of HIV screens provided to User Population patients during the report period, where the patient was not diagnosed with HIV any time prior to the screen. This does not include refusals of HIV screening.
   
   **Note:** This numerator does not include refusals. No denominator and is a total count only, not a percentage.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**HIV**

- Any of the following documented any time prior to the end of the report period
  - POV or Problem List 042, 042.0–044.9 (old codes), 079.53, V08, 795.71
• **Pregnancy**: At least 2 visits with POV or problem diagnosis: (V22.0–V23.9, V72.42, 640.*–649.*, 651.*–676.*) during the past 20 months **from the end of the Report Period, where the primary provider is not a CHR (Provider code 53)**. Pharmacy-only visits (Clinic Code 39) will not count toward these **two visits**. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period. The time period is extended to include patients who were pregnant during the report period but whose initial diagnoses (and HIV test) were documented prior to report period.

• **Miscarriage**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV 630, 631, 632, 633*, 634*
  - CPT 59812, 59820, 59821, 59830

• **Abortion**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV 635*, 636*, 637*
  - CPT 59100, 59120, 59130, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260–S2267
  - Procedure 69.01, 69.51, 74.91, 96.49

**HIV Screening**

• CPT 86689, 86701–86703, 87390, 87391, 87534–87539

• LOINC taxonomy

• Site-populated taxonomy BGP HIV TEST TAX

• Refusal of any laboratory test in site-populated taxonomy BGP HIV TEST TAX. For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted

• **HIV Screening Refusals**: Refusal of any laboratory test in site-populated taxonomy BGP HIV TEST TAX
Note: The time frame for both screening and refusals for the pregnant patient’s denominator is anytime during the past 20 months and for User Population patients 13–64 is anytime during the report period. Refusals are allowed during the past 20 months for pregnant patients (vs. only during the report period) in the event the patient is at the end of her pregnancy at the beginning of the report period and refused the HIV test earlier in her pregnancy during the previous year.

GPRA 2011 Description

During FY 2011, achieve the tentative target rate of 79.9% for the proportion of pregnant patients who are screened for HIV.

Patient List

List of pregnant or User Population patients 13–64 without documented HIV test or refusal.

2.8.2 HIV Quality of Care

No changes from Version 10.0 Patch 1

Owner/Contact

Drs. Scott Giberson, Marie Russell, and Jonathan Iralu

National Reporting

Not reported nationally

Denominator

User Population patients 13 and older with at least 2 direct care visits, (i.e., not contract/CHS) during the report period with HIV diagnosis and 1 HIV visit in last 6 months.

Numerators

1. Patients who received CD4 test only (without HIV viral load) during the report period.
2. Patients who received HIV Viral load only (without CD4), during the report period.
3. Patients who received both CD4 and HIV viral load tests during the report period.
4. Total Numerators 1, 2 and 3.

Definitions

Age

Age is calculated at beginning of the report period
HIV
POV or Problem List 042, 042.0–044.9 (old codes), 079.53, V08, or 795.71

Lab Test CD4
- CPT 86359, 86360, 86361
- LOINC taxonomy
- Site-populated taxonomy BGP CD4 TAX

HIV Viral Load
- CPT 87536, 87539
- LOINC taxonomy
- Site-populated taxonomy BGP HIV VIRAL TAX

Patient List
List of patients 13 and older diagnosed with HIV, with CD4 test, if any.

2.8.3 Chlamydia Testing

No changes from Version 10.0 Patch 1

Owner/Contact
Epidemiology Program/Dr. Jim Cheek, Lori DeRavello, MPH

National Reporting
Not reported nationally

Denominator
1. Female Active Clinical patients ages 16 through 25, broken down into age groups 16–20 and 21–25.
2. Female User Population patients ages 16 through 25, broken down into age groups 16–20 and 21–25.

Numerator
1. Patients tested for Chlamydia trachomatis during the report period.

Definitions

Age:
Age is calculated at beginning of the report period

Chlamydia
- V73.88, V73.98
- CPT: 86631, 86632, 87110, 87270, 87320, 87490–87492, 87810
• Site-populated taxonomy BGP GPRA CHLAMYDIA TESTS
• LOINC taxonomy

Patient List
List of patients with documented Chlamydia screening, if any.

2.8.4 Sexually Transmitted Infection (STI) Screening

No changes from Version 10.0 Patch 1

Owner/Contact
Dr. Scott Giberson

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators
1. Screenings needed for incidents of key STIs for Active Clinical patients that occurred during the period 60 days prior to the beginning of the report period through the first 300 days of the report period. Key STIs defined as Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Broken down by gender.
2. Chlamydia screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.
3. Gonorrhea screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.
4. HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.
5. Syphilis screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

Numerators
1. No denominator; count only. The total count of Active Clinical patients who were diagnosed with one or more key STIs during the period 60 days prior to the report period through the first 300 days of the report period. Broken down by gender.
2. No denominator; count only. The total count of separate key STI incidents for Active Clinical patients during the defined period. Broken down by gender.
3. For use with denominator #1: Total number of needed screenings performed or refused from one month prior to the date of relevant STI incident through two months after.
   • Number of documented screening refusals
4. For use with denominator #2: Number of needed Chlamydia screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.
   - Number of documented screening refusals

5. For use with denominator #3: Number of needed Gonorrhea screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.
   - Number of documented screening refusals

6. For use with denominator #4: Number of needed HIV/AIDS screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.
   - Number of documented screening refusals

7. For use with denominator #5: Number of needed Syphilis screenings performed or refused from one month prior to the date of first STI diagnosis of each incident through two months after.
   - Number of documented screening refusals

Definitions

**Key STIs**

Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Key STIs defined with the following POVS:

- Chlamydia: 078.8*, 079.88, 079.98, 099.41, 099.50–099.59
- Gonorrhea: 098.0–098.89
- HIV/AIDS: 042, 042.0-044.9, 079.53, 795.71, V08
- Syphilis: 090.0–093.9, 094.1–097.9

**Logic for Identifying Patients Diagnosed with Key STI (Numerator #1)**

Any patient with one or more diagnoses of any of the key STIs defined above during the period 60 days prior to the beginning of the report period through the first 300 days of the report period.

**Logic for Identifying Separate Incidents of Key STIs (Numerator #2)**

One patient may have one or multiple occurrences of one or multiple STIs during the year. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see definition above) occurring between 60 days prior to the beginning of the report period through the first 300 days of the report period. A second incident of the same STI is counted if another diagnosis with the same STI occurs two months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.
Example of Patient with Multiple Incidents of Single STI:

<table>
<thead>
<tr>
<th>Date</th>
<th>Visit</th>
<th>Total Incidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/10</td>
<td>Patient screened for Chlamydia</td>
<td>0</td>
</tr>
<tr>
<td>08/08/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>10/15/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>10/25/10</td>
<td>Follow-up for Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>11/15/10</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>03/01/11</td>
<td>Patient diagnosed with Chlamydia</td>
<td>3</td>
</tr>
</tbody>
</table>

**Denominator Logic for Needed Screenings (Denominator #1)**

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed screening tests denominator, the count will be derived from the number of separate STI incidents and the type(s) of screenings recommended for each incident. The recommended screenings for each key STI are listed in the following table:

<table>
<thead>
<tr>
<th>STI</th>
<th>Screenings Needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia</td>
<td>Gonorrhea, HIV/AIDS, Syphilis</td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>Chlamydia, HIV/AIDS, Syphilis</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>Chlamydia, Gonorrhea, Syphilis</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Chlamydia, Gonorrhea, HIV/AIDS</td>
</tr>
</tbody>
</table>

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

- The patient has a documented STI diagnosis corresponding to the screening type in the same time period. For example, a patient with both a Chlamydia and a gonorrhea diagnosis on the same visit does not need the recommended Chlamydia screening based on the gonorrhea diagnosis.

- Only one screening for each type of STI is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening each is needed for HIV/AIDS and Syphilis.

- A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.
**Numerator Logic**

To be counted in the numerator, each needed screening in the denominator must have a corresponding lab test or test refusal documented in the period from one month prior to the relevant STI diagnosis date through two months after the STI incident.

- **Chlamydia Screening:** Any of the following during the specified time period:
  - POV V73.88, V73.98
  - CPT 86631–86632, 87110, 87270, 87320, 87490–87492, 87810
  - Site-populated taxonomy BGP CHLAMYDIA TESTS TAX
  - LOINC taxonomy

- **Gonorrhea Screening:** Any of the following during the specified time period:
  - CPT 87590–87592, 87850
  - Site-populated taxonomy BKM GONORRHEA TEST TAX
  - LOINC taxonomy

- **HIV/AIDS Screening:** Any of the following during the specified time period:
  - CPT 86689, 86701–86703, 87390–87391, 87534–87539
  - Site-populated taxonomy BGP HIV TEST TAX
  - LOINC taxonomy

- **Syphilis Screening:** Any of the following during the specified time period:
  - CPT 86592–86593, 86781, 87285
  - Site-populated taxonomy BKM FTA-ABS TESTS TAX or BKM RPR TESTS TAX
  - LOINC taxonomy

- **Refusal of Any Screening:** Any refusal type (REF, NMI, etc.) for any of the four screening tests as defined above during the specified time period.

**Logic Examples**

- Example of Patient with Single Diagnosis of Single STI
  - 08/01/10: Patient screened for Chlamydia
  - 08/08/10: Patient diagnosed with Chlamydia–three screens needed: Gonorrhea, HIV/AIDS, Syphilis
  - 08/13/10: Patient screened for Gonorrhea, HIV/AIDS, Syphilis
  - Result: Denominator: Three screens needed, Numerator: Three screens performed

- Example of Patient with Multiple Diagnoses of Single STI
  - 08/01/10: Patient screened for Chlamydia
- 08/08/10: Patient diagnosed with Chlamydia (Incident #1) – three screens needed: Gonorrhea, HIV/AIDS, Syphilis
- 08/13/10: Patient screened for Gonorrhea, HIV/AIDS, Syphilis
- 12/01/10: Patient screened for Chlamydia
- 12/08/10: Patient diagnosed with Chlamydia (Incident #2) – three screens needed: Gonorrhea, HIV/AIDS, Syphilis
- Result: Denominator: six screens needed (two each of three types), Numerator: three screens performed (one each of three types)

• Example of Patient with Single Diagnosis of Multiple STIs
  - 10/15/10: Patient screened for Chlamydia, Gonorrhea, HIV/AIDS, Syphilis
  - 10/18/10: Patient diagnosed with Chlamydia – three screens needed: Gonorrhea, HIV/AIDS, Syphilis
  - 10/20/10: Patient diagnosed with Syphilis – removes needed screen for Syphilis (see above)
  - Result: Denominator: two screens needed, Numerator: two screens performed prior to triggering diagnoses but within timeframe)

• Example of Patient with Multiple Diagnoses of Multiple STIs
  - 06/15/05: Patient diagnosed with HIV/AIDS
  - 08/01/10: Patient screened for Chlamydia and Gonorrhea
  - 08/08/10: Patient diagnosed with Chlamydia and Gonorrhea (Incident #1) – 1 screen needed: Syphilis (HIV/AIDS not needed since prior diagnosis)
  - 08/08/10: Patient screened for HIV/AIDS and Syphilis - since only the Syphilis screen is needed, the HIV/AIDS screen is not counted at all
  - 12/01/10: Patient screened for Chlamydia
  - 12/08/10: Patient diagnosed with Chlamydia (Incident #2 – two screens needed: Gonorrhea and Syphilis
  - 12/10/10: Patient screened for Syphilis
  - Result: Denominator: three screens needed (two Syphilis and one Gonorrhea), Numerator: two screens performed (two Syphilis)

**Patient List**

List of patients diagnosed with one or more STIs during the defined time period with related screenings.
2.9 Other Clinical Measures Group

2.9.1 Osteoporosis Management

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Drs. Bruce Finke and Lisa Sumner

National Reporting
Not reported nationally

Denominator
Female Active Clinical patients ages 67 and older who had a new fracture occurring six months (180 days) prior to the report period through the first six months of the report period with no osteoporosis screening or treatment in year prior to the fracture.

Numerator
Patients treated or tested for osteoporosis after the fracture.

Definitions

Age
Age is calculated at the beginning of the report period.

Fracture
Does not include fractures of finger, toe, face, or skull. CRS will search for the first (i.e., earliest) fracture during the period six months (180) days prior to the beginning of the report period and the first six months of the report period. If multiple fractures are present, only the first fracture will be used.

The Index Episode Start Date is the date the fracture was diagnosed. If the fracture was diagnosed at an outpatient visit (Service Category A, S, or O), the Index Episode Start Date is equal to the Visit Date. If diagnosed at an inpatient visit (Service Category H), the Index Episode Start Date is equal to the Discharge Date.

Denominator Exclusions

- Patients receiving osteoporosis screening or treatment in the year (365 days) prior to the Index Episode Start Date. Osteoporosis screening or treatment is defined as a Bone Mineral Density (BMD) test (see below for codes) or receiving any osteoporosis therapy medication (see below for codes).
- Patients with a fracture diagnosed at an outpatient visit, which also had a fracture within 60 days prior to the Index Episode Start Date.
- Patients with a fracture diagnosed at an inpatient visit, which also had a fracture within 60 days prior to the ADMISSION DATE.
**Osteoporosis Treatment and Testing**

For fractures diagnosed at an outpatient visit:

- A nondiscontinued prescription within 6 months (180 days) of the Index Episode Start Date (i.e., visit date) or
- A BMD test within six months of the Index Episode Start Date.

For fractures diagnosed at an inpatient visit, a BMD test performed during the inpatient stay.

**Fracture codes**

- POV 733.1*, 805*–806*, 807.0*–807.4, 808*–815*, 818*–825*, 827*, 828*
- Procedure 79.01–79.03, 79.05–79.07, 79.11–79.13, 79.15–79.17, 79.21–79.23, 79.25–79.27, 79.31–79.33, 79.35–79.37, 79.61–79.63, 79.65–79.67, 81.65, 81.66

**BMD Test**

- CPT 77078, 76070 (old code), 77079, 76071 (old code), 77080, 76075 (old code), 77081, 76076 (old code), 77083, 76078 (old code), 76977, 78350, 78351, G0130
- Procedure 88.98
- POV V82.81

**Osteoporosis Treatment Medication**

Medication taxonomy BGP HEDIS OSTEOPOROSIS MEDS.

- Medications are Alendronate, Alendronate-Cholecalciferol (Fosomax Plus D), Ibandronate (Boniva), Risedronate, Calcitonin, Raloxifene, Estrogen, Injectable Estrogens, and Teriparatide. *Medications must not have a comment of RETURNED TO STOCK.*

**Patient List**

List of female patients with new fracture who have had osteoporosis treatment or testing, if any.

### 2.9.2 Osteoporosis Screening in Women

**No changes from Version 10.0 Patch 1**
Owner/Contact
Drs. Bruce Finke and Lisa Sumner

National Reporting
Not reported nationally

Denominator
Female Active Clinical patients ages 65 and older without a documented history of osteoporosis.

Numerator
1. Patients who had osteoporosis screening documented in the past two years, including documented refusals in past year.
   • Patients with documented refusal in past year

Definitions

Age
Age is calculated at the beginning of the report period

Patients without Osteoporosis
No osteoporosis diagnosis ever (POV 733.*)

Osteoporosis Screening
Any one of the following in the past two years or documented refusal in the past year:

- Central DEXA: CPT 77080, 76075 (old code)
- Peripheral DEXA: CPT 77081, 76076 (old code)
- SEXA: CPT G0130
- Central CT: CPT 77078, 76070 (old code)
- Peripheral CT: CPT 77079, 76071 (old code)
- US Bone Density: CPT 76977
- Quantitative CT: Procedure 88.98
- POV V82.81 Special screening for other conditions, Osteoporosis

Patient List
List of female patients ages 65 and older with osteoporosis screening, if any.

2.9.3 Rheumatoid Arthritis Medication Monitoring

Changes from Version 10.0 Patch 1, as noted.
Owner/Contact
Dr. Lisa Sumner

National Reporting
Not reported nationally

Denominator
Active Clinical patients ages 16 and older diagnosed with rheumatoid arthritis (RA) prior to the report period and with at least two RA-related visits any time during the report period who were prescribed maintenance therapy medication chronically during the report period.

Numerator
Patients who received appropriate monitoring of chronic medication during the report period.

Definitions

**Age**
Age is calculated at the beginning of the report period

**RA**
Diagnosis (POV or Problem List) 714.* prior to the report period, and at least two RA POVs during the report period.

**Maintenance Therapy Medications and Monitoring**
For all maintenance therapy medications except intramuscular gold, each medication must be prescribed within the past 465 days of the end of the report period (i.e., the Medication Period) and the sum of the days supply =>348. This means the patient must have been on the medication at least 75% of the medication period. The following two examples illustrate this logic. All medications must not have a comment of RETURNED TO STOCK.

- **Example of Patient Not on Chronic Medication (not included in Denominator)**
  Report period: Jan 1–Dec 31, 2011
  
  **Medication Prescribed:**
  - Total Days Supply=270. 270 is not >348. Patient is not considered on chronic medication and is not included in the denominator.

- **Example of Patient on Chronic Medication (included in Denominator):**
Report period: Jan 1–Dec 31, 2011


**Medication Prescribed:**

  - Days Supply=180.

Total Days Supply=360. 360 is >348. Patient is considered on chronic medication and is included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the medication period. However, for all medications, there must be at least one prescription filled during the Report period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

For intramuscular gold, the patient must have 12 or more injections during the report period.

**Appropriate Monitoring of Rheumatoid Arthritis Medications**

Appropriate monitoring is defined with laboratory tests and varies by medication, as shown in the table below. If patient is prescribed two or more types of medications, patient must meet criteria for all of the medications.

**Maintenance Therapy Medications**

Medications shown in table below except for Gold, Intramuscular, all medications requiring more than one of each type of test during the report period, there must be a minimum of 10 days between tests. For example, if a Sulfasalazine test was performed on March 1, March 7, and March 21, 2011, the March 7 test will not be counted since it was performed only 6 days after the March 1 test.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Required Monitoring Test(s) and Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold, Intramuscular</td>
<td>CBC and Urine Protein on same day as each injection during report period.</td>
</tr>
<tr>
<td>Azathioprine or Sulfasalazine</td>
<td>4 CBCs during the report period.</td>
</tr>
<tr>
<td>Leflunomide or Methotrexate</td>
<td>6 each of CBC, Serum Creatinine, and Liver Function Test during the report period.</td>
</tr>
<tr>
<td>Medication</td>
<td>Required Monitoring Test(s) and Frequency</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cyclosporin</td>
<td>CBC, Liver Function Tests, and Potassium within past 180 days from report period end date. 12 Serum Creatinine tests during the report period</td>
</tr>
<tr>
<td>Gold, Oral or Penicillamine</td>
<td>4 each of CBC and Urine Protein during the report period.</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>CBC within past 180 days from report period end date.</td>
</tr>
</tbody>
</table>

The medications in the previous table are defined with medication taxonomies:

- BGP RA IM GOLD MEDS
- BGP RA AZATHIOPRINE MEDS
- BGP RA LEFLUNOMIDE MEDS
- BGP RA METHOTREXATE MEDS
- BGP RA CYCLOSPORINE MEDS
- BGP RA ORAL GOLD MEDS
- BGP RA MYCOPHENOLATE MEDS
- BGP RA PENICILLAMINE MEDS
- BGP RA SULFASALAZINE MEDS

**NSAID Medications**

- All of the following NSAID medications must have Creatinine, Liver Function Tests, and CBC during the report period:
  - Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celoxib.
  - All of these medications except aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS
  - Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

**Glucocorticoid Medications**

- Dexamethasone, Methylprednisolone, Prednisone, Hydrocortisone, Betamethasone, Prednisonolone, Triamcinolone
- These medications defined with medication taxonomy BGP RA GLUCOCORTICOIDS MEDS
- Glucocorticoids must have a glucose test, which must be performed during the report period

**Example of Patient Not Included in Numerator**

Medications Prescribed and Required Monitoring:
− Gold, Oral, last Rx Jun 15, 2011. Requires CBC and Urine Protein within past 90 days of report period end date.
− CBC performed on Dec 1, 2011, which is within past 90 days of report period end date of Dec 31, 2011. No Urine Protein performed during that period.
− Patient is not in numerator.

Example of Patient Included in Numerator
Medications Prescribed and Required Monitoring:
− Diclofenac, last Rx Sep 1, 2011. Requires LFT and CBC during report period. Mycophenolate, last Rx Mar 10, 2011. Requires CBC within past 180 days from report period end date.
− LFT and CBC performed during report period. CBC performed Nov 1, 2011, which is within past 180 days of report period end date of Dec 31, 2011.
− Patient is in numerator.

Monitoring Test Definitions

CBC (Complete Blood Count)
− CPT 85025, 85027
− Site-populated taxonomy BGP CBC TESTS
− LOINC taxonomy

Urine Protein
− Site-populated taxonomy DM AUDIT URINE PROTEIN TAX
− LOINC taxonomy

Serum Creatinine
− CPT 82540, 82565–75
− Site-populated taxonomy DM AUDIT CREATININE TAX;
− LOINC taxonomy

Liver Function Tests: Any one of the following:

• ALT
  − CPT 84460
  − Site-populated taxonomy DM AUDIT ALT
  − LOINC taxonomy

• AST
  − CPT 84450
  − Site-populated taxonomy DM AUDIT AST
  − LOINC taxonomy; or

• Liver Function
– CPT 80076
– Site-populated taxonomy BGP LIVER FUNCTION, or
– LOINC taxonomy

**Glucose**
– CPT 82947, 82948, 82950, 82951, 82952, 82962
– Site-populated taxonomy DM AUDIT GLUCOSE TESTS TAX; or
– LOINC taxonomy

**Potassium**
– CPT 84132
– Site-populated taxonomy BGP POTASSIUM; or
– LOINC taxonomy

**Patient List**
List of RA patients 16 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with “YES:” and patients who did not meet the measure are prefixed with “NO:”. The chronic medications and all laboratory tests the patient did have are displayed.

### 2.9.4 Osteoarthritis Medication Monitoring

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**
Dr. Charles (Ty) Reidhead

**National Reporting**
Not reported nationally

**Denominator**
Active Clinical patients ages 40 and older diagnosed with osteoarthritis (OA) prior to the report period and with at least two OA-related visits any time during the report period and prescribed maintenance therapy medication chronically during the report period.

**Numerator**
1. Patients who received appropriate monitoring of chronic medication during the report period.

**Definitions**

**Age**
Age is calculated at the beginning of the report period.
Osteoarthritis (OA)

Diagnosis (POV or Problem List) 715.* prior to the report period, and at least two OA POVs during the report period.

Maintenance Therapy Medications and Monitoring

For all maintenance therapy medications, each medication must be prescribed within the past 465 days of the end of the report period (i.e., the medication period) and the sum of the day’s supply =>348. This means the patient must have been on the medication at least 75% of the medication period. The following two examples illustrate this logic. Medications must not have a comment of RETURNED TO STOCK.

- **Example of Patient Not on Chronic Medication (not included in Denominator):**
  - Medication Prescribed:
    - Total Days Supply=270. 270 is not >348. Patient is not considered on chronic medication and is not included in the denominator.

- **Example of Patient on Chronic Medication (included in Denominator):**
  - Medication Prescribed:
    - Total Days Supply=360. 360 is >348. Patient is considered on chronic medication and included in denominator.

The days supply requirement may be met with a single prescription or from a combination of prescriptions for the same medication that were filled during the medication period. However, for all medications, there must be at least one prescription filled during the report period.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.
• Appropriate monitoring of osteoarthritis medications is defined with laboratory tests and varies by medication, as shown in below.

**Maintenance Therapy Medications**

• NSAID Medications: All of the following NSAID medications must have Creatinine, Liver Function Tests, and CBC during the report period:
  - Diclofenac, Etodolac, Indomethacin, Ketorolac, Sulindac, Tolmetin, Meclofenamate, Mefanamic Acid, Nabumetone, Meloxicam, Piroxicam, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Oxaprozin, Aspirin, Choline Magnesium Trisalicylate, Diflunisil, Magnesium Salicylate, Celecoxib
  - All of these medications except aspirin are defined with medication taxonomy BGP RA OA NSAID MEDS
  - Aspirin defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

• All NSAID medications must have Creatinine, Liver Function Tests and CBC during the report period.

• **Example of Patient Not Included in Numerator:**
  Medication Prescribed and Required Monitoring:
  - Diclofenac, last Rx Jun 15, 2011. Requires Creatinine, LFT, and CBC during report period
  - Only the LFT was performed during report period
  - Patient is not in numerator

• **Example of Patient Included in Numerator:**
  Medications Prescribed and Required Monitoring:
  - Diclofenac, last Rx Sep 1, 2011. Requires Creatinine, LFT, and CBC during report period
  - Creatinine, LFT, and CBC performed during report period
  - Patient is in the numerator

**Monitoring Test Definitions**

• **Serum Creatinine:**
  - CPT 82540, 82565–75
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT CREATININE TAX

• **CBC (Complete Blood Count):**
  - CPT 85025, 85027
  - Site-populated taxonomy BGP CBC TESTS
- LOINC taxonomy
- **Liver Function Tests**: Any one of the following:
  - ALT
    - CPT 84460
    - Site-populated taxonomy DM AUDIT ALT
    - LOINC taxonomy
  - AST
    - CPT 84450
    - Site-populated taxonomy DM AUDIT AST
    - LOINC taxonomy
  - Liver Function
    - CPT 80076
    - Site-populated taxonomy BGP LIVER FUNCTION
    - LOINC taxonomy

**Patient List**

List of OA patients 40 and older prescribed maintenance therapy medication with monitoring laboratory tests, if any. The numerator values for patients who meet the measure are prefixed with “YES:” and patients who did not meet the measure are prefixed with “NO:”. All laboratory tests the patient *did* have are displayed.

**2.9.5 Asthma**

**No changes from Version 10.0 Patch 1**

**Owner/Contact**

Drs. Charles (Ty) Reidhead and Charles North

**National Reporting**

Not reported nationally

**Denominators**

1. Active Clinical patients, broken out by age groups: <5, 5–64, 65 and older (HP 2010).
2. Numerator 1 (Patients who have had two asthma-related visits during the report period or with persistent asthma) broken out by age groups: <5, 5–64, 65 and older.

**Numerators**

1. Patients who have had two asthma-related visits during the report period or with persistent asthma.
- Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the report period.

**Definitions**

**Age**
Age is calculated at beginning of the report period.

**Asthma Visits**
Asthma visits are defined as diagnosis (POV) 493.*.

**Persistent Asthma**
Any of the following:
- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

**Hospitalizations**
Hospitalizations are defined as service category H with primary POV 493.*.

**Patient List**
List of patients diagnosed with asthma and any asthma-related hospitalizations.

### 2.9.6 Asthma Quality of Care

**Changes from Version 10.0 Patch 1, as noted.**

**Owner/Contact**
Drs. Charles (Ty) Reidhead and Charles North

**National Reporting**
Not reported nationally

**Denominator**
1. Active Clinical patients ages 5–56 with persistent asthma within the year prior to the beginning of the report period and during the report period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).
   - Active Clinical patients ages 5–9.
   - Active Clinical patients ages 10–17.
   - Active Clinical patients ages 18–56.
Numerator

1. Patients who had at least one dispensed prescription for preferred asthma therapy medication during the report period.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

- **Patients diagnosed with emphysema or COPD** at any time on or before the end of the report period are excluded from the denominator.

**Emphysema**

Any visit at any time on or before the end of the report period with POV codes: 492.*, 506.4, 518.1, 518.2.

**COPD**

Any visit at any time on or before the end of the report period with POV codes: 491.20, 491.21, 491.22, 493.2*, 496, 506.4.

**Persistent Asthma:**

Meeting any of the following four criteria below within the year prior to the beginning of the report period and during the report period:

- At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis 493.* (asthma)
- At least one acute inpatient discharge with primary diagnosis 493.* Acute inpatient discharge defined as Service Category of H
- At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.* and at least two asthma medication dispensing events (see definition below)
- At least four asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then must also have at least one visit with POV 493.* in the same year as the leukotriene modifier (i.e. during the report period or within the year prior to the beginning of the report period.), or

Meeting any of the following criteria below:

- Active entry in PCC Problem List for 493.* with Severity of 2, 3 or 4 at any time before the end of the report period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.
Dispensing Event

One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days’ supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4.

- **Asthma medication codes for denominator** defined with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtiphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, Metaproterenol, Pirbuterol. **Medications must not have a comment of RETURNED TO STOCK.**

Preferred Asthma Therapy

To be included in the numerator, patient must have a nondiscontinued prescription for preferred asthma therapy (see list of medications below) during the report period.

- **Preferred asthma therapy medication codes for numerator defined with medication taxonomy:** BGP HEDIS PRIMARY ASTHMA MEDS.
Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Bzclomethasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline). Medications must not have a comment of RETURNED TO STOCK.

Patient List
List of asthmatic patients with preferred asthma therapy medications, if any.

2.9.7 Asthma and Inhaled Steroid Use

Changes from Version 10.0 Patch 1, as noted.

Owner/Contact
Drs. Charles (Ty) Reidhead and Charles North

National Reporting
Not reported nationally

Denominator
Active Clinical patients ages 1 or older with persistent asthma or who have had two asthma-related visits during the report period. Broken down into age groups: 1–4, 5–19, 20–44, 45–64, and 65+.

Numerator
Patients prescribed an inhaled corticosteroid during the report period.

Definitions

Age
Age of the patient is calculated at the beginning of the report period

Denominator Exclusion
Patients with intermittent asthma defined as any of the following:
- An Active entry in PCC Problem List for 493.* with a Severity of 1 at any time before the end of the report period, or
- Most recent visit-related asthma entry (i.e. V Asthma) with Severity of 1 documented any time before the end of the report period.
Asthma

- CRS will first search to see if the patient has persistent asthma, which is defined as any of the following:
  - An Active entry in PCC Problem List for 493.* with a Severity of 2, 3, or 4 at any time before the end of the report period or
  - Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the report period.

- If the patient does not meet any of the above criteria, then CRS will search for two asthma-related visits during the report period. Asthma-related visit defined as any primary or secondary POV of asthma 493.*.

**Note:** For facilities not using asthma staging (severity assessment) in the PCC Problem List, CRS will rely on visit criteria for this assessment. This will result in patients with intermittent asthma being included in the denominator. The Expert Guideline driven method for managing patients with asthma is by staging them in the PCC Problem List. Doing so will improve the accuracy of the information reported by CRS.

Inhaled Corticosteroid

To be included in the numerator, patient must have a non-discontinued prescription for an inhaled corticosteroid during the report period. Inhaled corticosteroid medications defined with medication taxonomy BGP ASTHMA INHALED STEROIDS.

- Medications are: Mometasone (Asmanex), Beclovent, Qvar, Vancenase, Vanceril, Vanceril DS, Bitolterol (Tornalate), Pulmicort, Pulmicort Respules, Pulmicort Turbohaler, Salmeterol/fluticasone (Advair), Triamcinolone (Azmacort), Fluticasone (Flovent), Budesonide-Formoterol (Symbicort).

*Medications must not have a comment of RETURNED TO STOCK.*

Patient List

List of patients with asthma with inhaled corticosteroid prescription, if any.

### 2.9.8 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation

**No changes from Version 10.0 Patch 1**

**Owner/Contact**

Dr. Charles (Ty) Reidhead
Denominators

Number of visits for User Population patients ages 18 and older diagnosed with community-acquired bacterial pneumonia at an outpatient visit during the report period.

Numerators

1. Number of visits where patients had oxygen saturation documented and reviewed.
2. Number of visits where patients refused oxygen saturation assessment.
3. Number of visits where patients did not have their oxygen saturation documented and reviewed.

Definition

Age

Age of the patient is calculated at the beginning of the report period.

Community-Acquired Bacterial Pneumonia

- Non-CHS outpatient visit (defined as (visit) Type not equal to "C" and Service Category of A (Ambulatory), S (Day Surgery), or O (Observation)) with POV 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39, 482.40, 482.41, 482.42, 482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 483.0, 483.1, 483.8, 485, 486, or 487.0.
- If a patient has more than one visit for community-acquired bacterial pneumonia during the report period, each visit will be counted as long as it has been more than 45 days since the date of the prior visit. For example, a patient was diagnosed on January 1, 2008 and 35 days later he was diagnosed again with pneumonia. That second diagnosis does not count as a separate visit. However, if the patient were diagnosed again on February 16, 2008 (46 days after onset), that diagnosis counts as a separate visit. Because RPMS does not store the date of onset, visit date will be used as a surrogate for onset date.

Oxygen Saturation Assessment

- Having any of the following arterial blood gas (ABG) or pulse oximetry tests performed at the visit:
  - V Measurement O2 Saturation
  - CPT 94760–94762, 82803, 82805, 82810, or 3028F, where 3028F has no modifier of 1P, 2P, 3P, or 8P
  - Laboratory test ABG
  - Site-populated lab taxonomy BGP CMS ABG TESTS
  - LOINC taxonomy
Refusal of Oxygen Saturation Assessment
Patients whose oxygen saturation was not assessed due to a patient refusal of assessment on visit date. Refusal is defined as refusal of any of the tests listed above.

No Assessment
Patients whose oxygen saturation was not assessed or refused.

Patient List
Patients with community-acquired bacterial pneumonia, with oxygen saturation assessment or documented reason for no assessment, if any.

2.9.9 Chronic Kidney Disease Assessment

No changes from Version 10.0 Patch 1

Owner/Contact
Kidney Disease Program/Dr. Andrew Narva

Denominator:
Active Clinical patients ages 18 and older with serum creatinine test during the report period.

Numerators:
1. Patients with Estimated GFR.
   • Patients with GFR less than (<) 60.
   • Patients with normal GFR (i.e. >=60).

Definitions:

Age
Age is calculated at beginning of the report period.

Creatinine
• CPT 82540, 82565–75
• LOINC taxonomy
• Site-populated taxonomy DM AUDIT CREATININE TAX.

Estimated GFR (Glomerular Filtration Rate)
• Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
• LOINC taxonomy
• For the GFR <60 numerator, CRS will include GFR results containing a numeric value less than 60 or with a value of "<60". For the normal GFR (>=60) numerator, CRS will include GFR results containing a numeric value equal to or greater than 60 or with a value of ">60"

Patient List:
List of patients with Creatinine test, with GFR and value, if any.

2.9.10 Prediabetes/Metabolic Syndrome

*Changes from Version 10.0 Patch 1, as noted.*

Owner/Contact
Drs. Stephen J. Rith Najarian and Kelly Moore

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominator
Active Clinical patients ages 18 and older diagnosed with prediabetes/metabolic syndrome without a documented history of diabetes.

Numerator
1. Patients with all screenings (BP, LDL, fasting glucose, nephropathy assessment, tobacco screening, BMI, lifestyle counseling, and depression screening)
2. Patients with BP documented at least twice during the report period.
3. Patients with LDL completed, regardless of result, during the report period.
4. Patients with fasting glucose test, regardless of result, during the report period.
5. Patients with nephropathy assessment, defined as an estimated GFR and a quantitative urinary protein assessment (changed from positive urine protein or any microalbuminuria) during the report period or with evidence of diagnosis and/or treatment of ESRD at any time before the end of the report period.
6. Patients who have been screened for tobacco use during the report period.
7. Patients for whom a BMI could be calculated, including refusals in the past year.
8. Patients who have received any lifestyle adaptation therapy, including medical nutrition counseling, or nutrition, exercise or other lifestyle education during the report period.
9. Patients screened for depression or diagnosed with a mood disorder at any time during the report period, including documented refusals in past year.
Definitions

**Age**

Age is calculated at beginning of the report period.

**Prediabetes/Metabolic Syndrome:**

- **Diagnosis of prediabetes/metabolic syndrome,** defined as: two visits during the report period with POV 277.7, or
- One each of at least three different conditions listed below, occurring during the report period except as otherwise noted:
  - BMI => 30 or Waist Circumference >40 inches for men or >35 inches for women,
  - Triglyceride value =>150,
  - HDL value <40 for men or <50 for women,
  - Patient diagnosed with hypertension or mean BP value => 130/85 where systolic is =>130 or diastolic is =>85,
  - Fasting Glucose value =>100 and <126.

**Note:** Waist circumference and fasting glucose values will be checked last.

**Patients without Diabetes**

No diabetes diagnosis ever (POV 250.00-250.93).

**Tests/Other Definitions**

- **BMI**
  - CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the report period. For 19 through 50, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50, height and weight within last 2 years not required to be recorded on same day. Refusals include REF, NMI and UAS and must be documented during the past year. For ages 18 and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 and older, the height and the weight must be refused during the past year and are not required to be on the same visit.

- **Triglyceride**
  - LOINC taxonomy or
  - Site-populated taxonomy DM AUDIT TRIGLYCERIDE TAX with a non-null, numeric result

- **HDL**
  - CPT 83718
• Fasting Glucose
  – Denominator definition:
    – LOINC taxonomy
    – Site-populated taxonomy DM AUDIT FASTING GLUCOSE TESTS with a non-null, numeric result
  – Numerator definition:
    – POV 790.21
    – LOINC taxonomy
    – Site-populated taxonomy DM AUDIT FASTING GLUCOSE TESTS

• LDL
  – Finds last test done during the report period; defined as:
    – CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F
    – LOINC taxonomy
    – Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

• Blood Pressure
  CRS uses the mean of the last three BPs documented on non-ER visits during the report period. If three BPs are not available, use the mean of the last two non-ER BPs. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last three (or two) systolic values and dividing by three (or two). The mean Diastolic value is calculated by adding the diastolic values from the last three (or two) blood pressures and dividing by three (or two).

For the BP documented numerator, if CRS is not able to calculate a mean BP, it will search for CPT 3074F–3080F 3074F–3076F, 3078F–3079F) documented on a non-ER visit during the report period.

• Hypertension
  – Diagnosis of (POV or problem list) 401.* occurring prior to the report period, and at least one hypertension POV during the report period.

Nephropathy Assessment
• Estimated GFR: Any of the following:
  – Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or
  – LOINC taxonomy
• **Quantitative Urine Protein Assessment**: Any of the following:
  – CPT 82042, 82043, or 84156
  – LOINC taxonomy
  – Site-populated taxonomy BGP QUANT URINE PROTEIN

**Note:** Check with your laboratory supervisor to confirm that the names you add to your taxonomy reflect quantitative test values.

### End Stage Renal Disease Diagnosis/Treatment

End Stage Renal Disease diagnosis/treatment defined as any of the following ever:

- CPT 36145, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831–36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951–90970 or (old codes) 90918–90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308–G0327 *(old codes)*, G0392 *(old code)*, G0393 *(old code)*, or S9339
- POV 585.5, 585.6, V42.0, V45.1 (old code), V45.11, V45.12, or V56.*
- Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6*

### Tobacco Screening

At least one of the following during the report period:

- Any health factor for category Tobacco, **TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP), or TOBACCO (EXPOSURE)** documented during current report period
- Tobacco-related diagnoses (POV or current Active Problem List) 305.1, 305.1* (old codes), 649.00–649.04, or V15.82
- Dental Code 1320
- Any patient education code containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00-649.04, V15.82, **D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455, G8456, G8457, G8402 or G8453**
- CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, or 1036F, 1000F, G8455, G8456, G8457, G8402 or G8453

### Lifestyle Counseling

Any of the following during the report period:

- **Medical nutrition therapy** defined as: CPT 97802–97804, G0270, G0271; **Primary or secondary** provider codes 07, 29; Clinic codes 67 (dietary) or 36 (WIC)
• **Nutrition education** Defined as: POV V65.3 dietary surveillance and counseling; patient education codes ending "-N" (Nutrition) or "-MNT" (or old code "-DT" (Diet)) or containing V65.3, 97802–97804, G0270, or G0271

• **Exercise education** Defined as: POV V65.41 exercise counseling; patient education codes ending "-EX" (Exercise), or containing V65.41

• **Related exercise and nutrition education** Defined as: patient education codes ending ",-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00 or 278.01

**Depression Screening/Mood Disorder DX**

Any of the following during the report period:

• Depression Screening
  – Exam Code 36
  – POV V79.0
  – BHS Problem Code 14.1 (screening for depression)
  – V Measurement in PCC or BH of PHQ2 or PHQ9,
  – Refusal, defined as any PCC refusal in past year with Exam Code 36
  – Mood Disorder DX:
    – At least two visits in PCC or BHS during the report period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS
    – These POV codes are: 296.*, 291.89, 292.84, 293.83, 300.4, 301.13, or 311 or BHS POV 14 or 15

**Patient List**

List of patients 18 and older with Prediabetes/Metabolic Syndrome with assessments received, if any.

### 2.9.11 Medications Education

**No changes from Version 10.0 Patch 1**

**Owner/Contact**

Patient Education Program/Cheryl Peterson, RN

**National Reporting**

Not reported nationally
Denominator
Active Clinical patients with medications dispensed at their facility during the report period.

Numerator
Patients who were provided patient education about their medications in any location.

Definitions
1. **Patients receiving medications**: Are identified any entry in the VMed file for your facility.
2. **Medication Education**: Any Patient Education code containing “M-” or “-M” or Patient Education codes DMC-IN, FP-DPO, FP-OC, ASM-NEB, ASM-MDI, PL-NEB, PL-MDI, or FP-TD.

Patient List
List of patients receiving medications with med education, if any

### 2.9.12 Public Health Nursing

**No changes from Version 10.0 Patch 1**

Owner/Contact
Cheryl Peterson, RN

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators
1. User Population patients.
2. Number of visits to User Population patients by PHNs in any setting, including Home
   - Number of visits to patients age 0–28 days (Neonate)
   - Number of visits to patients age 29 days to 12 months (Infants)
   - Number of visits to patients ages 1–64 years
   - Number of visits to patients ages 65 and older (Elders)
   - Number of PHN driver/interpreter (Provider Code 91) visits.
3. Number of visits to User Population patients by PHNs in Home setting, broken down into age groups: 0-28 days (neonate), 29 days-12 months (infants), 1–64 years, 65 and older (elders).
   - Number of Home visits to patients age 0-28 days (Neonate)
   - Number of Home visits to patients age 29 days to 12 months (Infants)
- Number of Home visits to patients ages 1–64 years
- Number of Home visits to patients ages 65 and older (Elders)
- Number of PHN driver/interpreter (Provider Code 91) visits

**Numerator**

1. For User Population only, the number of patients in the denominator served by PHNs in any setting, including Home.
2. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting
3. For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.
4. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME setting.
5. No numerator: Count of visits only.

**Definitions**

**PHN Visit-Any Setting**
Any visit with Primary or Secondary Provider Codes 13 or 91.

**PHN Visit-Home**
Any visit with one of the following:
- Clinic Code 11 and a primary or secondary provider code of 13 or 91
- Location Home (as defined in Site Parameters) and a Primary or Secondary Provider Code 13 or 91

**Patient List**
List of patients with PHN visits documented.

**Numerator codes in patient list:**
- All PHN = Number of PHN visits in any setting
- Home = Number of PHN visits in home setting
- Driver All = Number of PHN driver/interpreter visits in any setting
- Driver Home = Number of PHN driver/interpreter visits in home setting
2.9.13 Breastfeeding Rates

No changes from Version 10.0 Patch 1.

Note: This measure is used in conjunction with the Childhood Weight Control GPRA measure to support the reduction of the incidence of childhood obesity.

Owner/Contact
Cheryl Peterson, RN

National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

Denominators
1. Active Clinical patients who are 45–394 days old.
2. PART: Active Clinical patients who are 45–394 days old who were screened for infant feeding choice at the age of two months (45–89 days).
3. Active Clinical patients who are 45–394 days old who were screened for infant feeding choice at the age of six months (165–209 days).
4. Active Clinical patients who are 45–394 days old who were screened for infant feeding choice at the age of nine months (255–299 days).
5. Active Clinical patients who are 45–394 days old who were screened for infant feeding choice at the age of 1 year (350–394 days)

Numerators
1. Patients who were screened for infant feeding choice at least once.
2. Patients who were screened for infant feeding choice at the age of two months (45–89 days).
3. Patients were screened for infant feeding choice at the age of six months (165–209 days).
4. Patients who were screened for infant feeding choice at the age of nine months (255–299 days).
5. Patients who were screened for infant feeding choice at the age of 1 year (350–394 days).
6. PART: Patients who, at the age of two months (45–89 days), were either exclusively or mostly breastfed.
7. Patients who, at the age of six months (165–209 days), were either exclusively or mostly breastfed.
8. Patients who, at the age of nine months (255–299 days), were either exclusively or mostly breastfed.
9. Patients who, at the age of 1 year (350–394 days), were either exclusively or mostly breastfed.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**Patient List**

List of patients 45–394 days old, with infant feeding choice value, if any.

### 2.9.14 Use of High Risk Medications in the Elderly

*Changes from Version 10.0 Patch 1, as noted.*

**Owner/Contact**

Dr. Bruce Finke

**National Reporting**

Not reported nationally

**Denominator**

**GPRA Developmental:** Active Clinical patients ages 65 and older, broken down by gender.

**Numerator**

1. **GPRA Developmental:** Patients who received at least one high risk medication for the elderly during the report period.
2. **GPRA Developmental:** Patients who received at least two different high risk medications for the elderly during the report period.

Definitions

**Age**

Age of the patient is calculated at the beginning of the report period.

**High Risk Medications for the Elderly (i.e. potentially harmful drugs)**

Defined with medication taxonomies:

- **BGP HEDIS ANTIANXIETY MEDS**
  - (Includes combination drugs) (Aspirin-Meprobamate, Meprobamate)
- **BGP HEDIS ANTIEMETIC MEDS**
  - (Scopolamine, Trimethobenzamide)
- **BGP HEDIS ANALGESIC MEDS**
- (Includes combination drugs) (Acetaminophen-diphenhydramine, diphenhydramine-magnesium salicylate, Ketorolac)

- **BGP HEDIS ANTIHISTAMINE MEDS**

- **BGP HEDIS ANTIPSYCHOTIC MEDS**
  - (Thioridazine, Mesoridazine)

- **BGP HEDIS AMPHETAMINE MEDS**
  - (Aphetamine-dextroamphetamine, Benzphetamine, Dexmethylphenidate, Dextroamphetamine, Diethylproprion, Methamphetamine, Methylphenidate, Pemoline, Phendimetrazine, Phenteramine)

- **BGP HEDIS BARBITURATE MEDS**
  - (Amobarbital, Butobarbital, Mephobarbital, Pentobarbital, Phenobarbital, Secobarbital)

- **BGP HEDIS BENZODIAZEPINE MEDS**
  - (Includes combination drugs) (Amitriptyline-Chlordiazepoxide, Chlordiazepoxide, Chlordiazepoxide-clidinium, Diazepam, Flurazepam)

- **IBGP HEDIS CALCIUM CHANNEL MEDS**
  - (Nifedipine—short acting only)

- **BGP HEDIS GASTRO ANTISPASM MED**
  - (Dicyclomine, Propantheline)

- **BGP HEDIS BELLADONNA ALKA MEDS**

• BGP HEDIS SKL MUSCLE RELAX MED
  (Includes combination drugs) (ASA/cafeine/orphenadrine, ASA/carisoprodol/codeine, Aspirin-carisoprodol, Aspirin-meprobamate, Aspirin-methocarbamol, Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

• BGP HEDIS ORAL ESTROGEN MEDS
  (Includes combination drugs) (Conjugated estrogen, Conjugated estrogen-medroxyprogesterone, Esterified estrogen, Esterified estrogen-methyltestosterone, Estropipate)

• BGP HEDIS ORAL HYPOGLYCEMIC RX
  (Chlorpropamide)

• BGP HEDIS NARCOTIC MEDS
  (Includes combination drugs) (ASA/cafeine/prooxyphene, Acetaminophen-pentoazocine, Acetaminophen-prooxyphene, Belladonna-opium, Meperidine, Meperidine-promethazine, Naloxone-pentazocine, Pentazocine, Prooxyphene hydrochloride, Propoxyphene napsylate)

• BGP HEDIS VASODILATOR MEDS
  (Cyclandelate, Dipyridamole-short acting only, Ergot mesyloids, Isoxsuprine)

• BGP HEDIS OTHER MEDS AVOID ELD
  (Includes androgens and anabolic steroids, thyroid drugs, and urinary anti-infectives) (Methyltestosterone, Nitrofurantoin, Nitrofurantoin macrocrystals, Nitrofurantoin macrocrystals-monohydrate, Thyroid desiccated)

**Note:** For each medication, the days supply must be >0. If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e. visit date) from the V Medication Discontinued Date. Example: Rx Date=11/15/2011, Discontinued Date=11/19/2011, Recalculated # Days Prescribed=4. Medications must not have a comment of RETURNED TO STOCK.
Patient List
List of patients 65 and older with at least one prescription for a potentially harmful drug.

2.9.15 Functional Status in Elders

No changes from Version 10.0 Patch 1

Owner/Contact
Dr. Bruce Finke

National Reporting
Not reported nationally

Denominator
Active Clinical patients ages 55 and older, broken down by gender.

Numerator
Patients screened for functional status at any time during the report period.

Definitions

Age
Age of the patient is calculated at the beginning of the report period.

Functional Status
Any nonnull values in V Elder Care for the following:
- At least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence
- At least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the report period.

Patient List
List of patients =>55 with functional status codes, if any.

The following abbreviations are used in the Numerator column:
- TLT–Toileting
- BATH–Bathing
- DRES–Dressing
- XFER–Transfers
- FEED–Feeding
- CONT–Continence
- FIN–Finances
• COOK–Cooking
• SHOP–Shopping
• HSWK–Housework/Chores
• MEDS–Medications
• TRNS–Transportation

2.9.16 Fall Risk Assessment in Elders

No changes from Version 10.0 Patch 1

Owner/Contact
Dr. Bruce Finke

National Reporting
Not reported nationally

Denominator
Active Clinical patients ages 65 and older, broken down by gender.

Numerator
1. Patients who have been screened for fall risk or with a fall-related diagnosis in the past year, including documented refusals.
   • Patients who have been screened for fall risk in the past year.
   • Patients with a documented history of falling in the past year.
   • Patients with a fall-related injury diagnosis in the past year.
   • Patients with abnormality of gait/balance or mobility diagnosis in the past year.
   • Patients with a documented refusal of fall risk screening exam in the past year.

Definitions

Fall Risk Screen
Any of the following:
– Fall Risk Exam defined as: V Exam Code 37
– History of Falling defined as: POV V15.88 (Personal History of Fall)
– Fall-related Injury Diagnosis defined as: POV (Cause Codes #1–3) E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*
– Abnormality of Gait/Balance or Mobility defined as: POV 781.2, 781.3, 719.7, 719.70 (old code), 719.75–719.77 (old codes), 438.84, 333.99, 443.9
– Refusal defined as: Refusal Exam 37
Age

Age of the patient is calculated at the beginning of the report period.

Patient List

List of patients 65 years or older with fall risk assessment, if any.

2.9.17 Palliative Care

No changes from Version 10.0 Patch 1

Owner/Contact

Dr. Bruce Finke

National Reporting

Not reported nationally

Denominator

No denominator, count only.

Numerators

1. No denominator; count only. For patients meeting the Active Clinical definition, the total number of patients with at least one palliative care visit during the report period; broken down by age groups (<18, 15–54, 55 and older).

2. No denominator; count only. For patients meeting the Active Clinical definition, the total number of palliative care visits during the report period; broken down by age groups (<18, 15–54, 55 and older).

Definition

Age

Age is calculated at the beginning of the report period

Palliative Care Visit

POV V66.7

Patient List

List of patients with a palliative care visit.
Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

Phone: (505) 248-4371 or (888) 830-7280 (toll free)
Fax: (505) 248-4363
Web: http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm
Email: support@ihs.gov